U.S. patent application number 09/833450 was filed with the patent office on 2001-11-29 for heterocyclic compounds useful as nmda receptor selective subtype blockers.
Invention is credited to Alanine, Alexander, Buettelmann, Bernd, Jaeschke, Georg, Neidhart, Marie-Paule H., Pinard, Emmanuel, Wyler, Rene.
Application Number | 20010047031 09/833450 |
Document ID | / |
Family ID | 8168522 |
Filed Date | 2001-11-29 |
United States Patent
Application |
20010047031 |
Kind Code |
A1 |
Alanine, Alexander ; et
al. |
November 29, 2001 |
Heterocyclic compounds useful as NMDA receptor selective subtype
blockers
Abstract
The invention relates to compounds of formula 1 wherein Ar.sup.1
is pyridyl or phenyl, substituted by hydroxy, lower alkyl, halogen,
amino, nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the
group 2 wherein Z.sup.1 is a five membered heterocyclic ring, which
contains one or two heteroatoms, selected from N or O; R.sup.1 is
hydrogen, hydroxy or an oxo group; Ar.sup.2 is pyridyl or phenyl,
optionally substituted by hydroxy, lower alkyl, halogen, amino,
nitro, benzyloxy or lower alkoxy-lower alkoxy, or is the group 3
wherein Z.sup.2 is a five or six membered ring, which optionally
contains one or two heteroatoms, selected from N or O; and Q is
--S--, --S(O)-- or --S(O).sub.2--; X is a bond, --CH(OH)-- or
--(CH.sub.2).sub.n--; A is a bond or --(CHR).sub.m--; R is
hydrogen, halogen or hydroxy, independently from each other if m is
2 or 3; Y is --(CR.sub.2).sub.m--, --O--, --C.dbd.C--,
--C.ident.C--, piperidin-1-yl, pyrrolidin-1yl or
C.sub.4-C.sub.6-cycloalkyl, which rings are optionally substituted
by hydroxy; B is a bond, --O-- or --(CHR).sub.m; n is 1 or 2; and m
is 1 to 3 and pharmaceutically acceptable acid addition salts
thereof with the exception of compounds, wherein A and B are
simultaneously a bond and Y is --CHR--. The compounds may be used
in the treatment of neurodegenerative diseases.
Inventors: |
Alanine, Alexander;
(Schlierbach, FR) ; Buettelmann, Bernd;
(Schopfheim, DE) ; Neidhart, Marie-Paule H.;
(Hagenthal le Bas, FR) ; Jaeschke, Georg; (Basle,
CH) ; Pinard, Emmanuel; (Linsdorf, FR) ;
Wyler, Rene; (Zuerich, CH) |
Correspondence
Address: |
HOFFMANN-LA ROCHE INC.
PATENT LAW DEPARTMENT
340 KINGSLAND STREET
NUTLEY
NJ
07110
|
Family ID: |
8168522 |
Appl. No.: |
09/833450 |
Filed: |
April 12, 2001 |
Current U.S.
Class: |
514/424 ;
548/543 |
Current CPC
Class: |
C07D 211/54 20130101;
C07D 263/58 20130101; C07D 209/34 20130101; C07D 231/56 20130101;
A61P 25/14 20180101; A61P 43/00 20180101; A61P 25/04 20180101; A61P
25/16 20180101; A61P 21/04 20180101; C07D 207/12 20130101; C07D
205/04 20130101; A61P 25/28 20180101 |
Class at
Publication: |
514/424 ;
548/543 |
International
Class: |
A61K 031/40; C07D
207/24 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 20, 2000 |
EP |
00108610.7 |
Claims
1. A compound of formula 49wherein Ar.sup.1 is selected from the
group consisting of pyridyl and phenyl, pyridyl and phenyl
substituted by hydroxy, lower alkyl, halogen, amino, nitro,
benzyloxy or lower alkoxy-lower alkoxy, and the group 50wherein
Z.sup.1 is a five membered heterocyclic ring, which contains one or
two heteroatoms, selected from N or O; R.sup.1 is selected from
hydrogen, hydroxy and an oxo group; Ar.sup.2 is selected from the
group consisting of pyridyl and phenyl, pryridyl and phenyl
optionally substituted by hydroxy, lower alkyl, halogen, amino,
nitro, benzyloxy or lower alkoxy-lower alkoxy, and the group
51wherein Z.sup.2 is a five or six membered ring,, a five or six
membered ring which optionally contains one or two heteroatoms,
selected from N or O; and Q is --S--, --S(O)-- or--S(O).sub.2--; X
is a bond, --CH(OH)-- or --(CH.sub.2).sub.n--; A is a bond or
--(CHR).sub.m--; R is selected from hydrogen, halogen or hydroxy,
independently from each other if m is 2 or 3; Y is selected from
--(CR.sub.2).sub.m--, --O--, --C.dbd.C--, --C.ident.C--,
piperidin-1-yl, pyrrolidin-1-yl or C.sub.4-C.sub.6-cycloalkyl, and
piperidin-2-yl, pyrrolidin-1-yl or C.sub.4-C.sub.6-cycloalkyl rings
substituted by hydroxy; B is a bond, --O-- or --(CHR).sub.m; n is 1
or 2; and m is 1,2or3; and pharmaceutically acceptable acid
addition salts thereof with the exception of compounds, wherein A
and B are simultaneously a bond and Y is --CHR--.
2. A compound according to claim 1, wherein Ar.sup.1 is phenyl,
substituted by hydroxy, Q is --S--, Ar.sup.2 is phenyl and X is
--CH.sub.2--.
3. A compound according to claim 2, which is
(S)-4-[1-(4-phenyl-butyl)-pyr- rolidin-3-yl-sulfanyl]-phenol,
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-- sulfanyl]-phenol,
(R)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phen- ol, (2R,
3S) or (2S, 3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-s-
ulfanyl]-phenol, (2S, 3S) or (2R, 3
S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyr-
rolidin-3-yl-sulfanyl]-phenol,
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidin-3-yl- -sulfanyl]-phenol,
(3RS, 3RS) and (3RS, 3SR)-4-[1-(3-hydroxy-4-phenyl-buty-
l)-pyrrolidin-3-yl-sulfanyl]-phenol, (2S, 3R) or (2R,
3R)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol,
(2RS,3
S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol
or (2RS
,3R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phe-
nol.
4. A compound according to claim 3 wherein the compound is
(S)-4-[1-(4-phenyl-butyl) -pyrrolidin-3-yl-sulfanyl]-phenol.
5. A compound according to claim 3 wherein the compound is
(2RS,3S)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
6. A compound according to claim 3 wherein the compound is
(R)-4-[1-(4-Phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol.
7. A compound according to claim 1, wherein Ar.sup.1 is phenyl,
substituted by hydroxy, Q is --S(O)--, Ar.sup.2 is phenyl and X is
--CH.sub.2.
8. A compound according to claim 7, which is selected from the
group consisting of (3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[l-(4-phenyl-buty- l)-pyrrolidine-3-sulfinyl]-phenol, (2R,3R,
S-oxide R)-4-[1-(2-fluoro-4-phe-
nyl-butyl)-pyrrolidine-3-sulfinyl]-phenol, (2R,3S, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]-phenol,
(2R,3S, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]-phenol or
(3S, S-oxide S) or (3S, S-oxide
R)-4-[1-(2,2-difluoro-4-phenyl-butyl)--
pyrrolidine-3-sulfinyl]-phenol.
9. The compound of claim 8 wherein the compound is (2S,3S, S-oxide
R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]-phenol.
10. A compound according to claim 1, wherein Ar.sup.1 is phenyl,
substituted by hydroxy, Q is --S(O).sub.2--, Ar.sup.2 is selected
from the group consisting of indanyl, phenyl, and indanyl and
phenyl substituted by methyl wherein X is --CH.sub.2-- or
--CH(OH)--.
11. A compound according to claim 10, which is selected from the
group consisting of
(S)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol, (2R, 3S)
and (2S,
3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
(3RS, cis) and (3RS,
trans)-4-[1-(3-benzyl-cyclobutyl)-pyrrolidine-3-sulf- onyl]-phenol,
(3RS, cis)-4-[1-(4-phenyl-cyclohexyl)-pyrrolidine-3-sulfonyl-
]-phenol,
(3RS,4RS)-4-(4-hydroxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrro-
lidin-3-ol,
(RS)-4-[1-(4-m-tolyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidine-3-sulfonyl]-phenol,
(R)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
(RS)-4-[1-(1-phenyl-piperidin-4-yl)-pyrrolidine-3-sulfonyl]-phenol
or (2R, 3S) or (2S,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidine-3-sulfon-
yl]-phenol.
12. A compound according to claim 11, wherein the compound is
selected from the group consisting of (2R, 3S) and (2S,
3S)-4-[1-(2-Fluoro-4-pheny-
l-butyl)-pyrrolidine-3-sulfonyl]-phenol.
13. A compound according to claim 11 wherein the compound is
selected from the group consisting of (3RS, cis) and (3RS,
trans)-4-[1-(3-Benzyl-cyclob-
utyl)-pyrrolidine-3-sulfonyl]-phenol.
14. A compound according to claim 11 wherein the compound is (3RS,
cis)-4-[1-(4-phenyl-cyclohexyl)-pyrrolidine-3-sulfonyl]-phenol>
15. A compound according to claim 11 wherein the compound is
selected from the group consisting of (2R, 3S) and (2S,
3S)-4-[1-(2-Hydroxy-2-indan-2-y-
l-ethyl)-pyrrolidine-3-sulfonyl]-phenol.
16. A compound acording to claim 11 wherein the compound is
(3RS,4RS)-4-(4-hydroxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolidin-3-o-
l.
17. A method of treatment of a disease state based on therapeutic
indications for NMDA receptor subtype specific blockers, which
include acute forms of neurodegeneration caused, e.g., by stroke
and brain trauma, and chronic forms of neurode generation such as
Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS
(amyotrophic lateral sclerosis) and neurodegeneration associated
with bacterial sclerosis) and neurodegeneration associated with
bacterial or viral infections comprising: administering an
effective amount of a medicament containing an effective amount of
a compound having the structure of 52formula I in a
pharmaceutically acceptable vehicle wherein Ar.sup.1 is selected
from the group consisting of pyridyl and phenyl, pyridyl and phenyl
substituted by hydroxy, lower alkyl, halogen, amino, nitro,
benzyloxy or lower alkoxy-lower alkoxy, and the group 53wherein
Z.sup.1 is a five membered heterocyclic ring, which contains one or
two heteroatoms, selected from N or O; R.sup.1 is selected from
hydrogen, hydroxy and an oxo group; Ar.sup.2 is selected from the
group consisting of pyridyl and phenyl, and pryridyl and phenyl
substituted by hydroxy, lower alkyl, halogen, amino, nitro,
benzyloxy or lower alkoxy-lower alkoxy, and the group 54wherein
Z.sup.2 is a five or six membered ring,, a five or six membered
ring, and a five or six member ring which contains one or two
heteroatoms, selected from N or O; and wherein Q is --S--, --S(O)--
or--S(O).sub.2--; X is a bond, --CH(OH)-- or --(CH.sub.2).sub.n--;
A is a bond or --(CHR).sub.m--; R is selected from hydrogen,
halogen or hydroxy, independently from each other if m is 2 or 3; Y
is selected from --(CR.sub.2).sub.m--, --O--, --C.dbd.C--,
--C.ident.C--, piperidin-1-yl, pyrrolidin-1-yl or
C.sub.4-C.sub.6-cycloal- kyl, and piperidin-2-yl, pryyolidin-1-yl
or C.sub.4-C.sub.6-cycloalkyl rings substituted by hydroxy; B is
selected from a bond, --O-- or --(CHR).sub.m; wherein n is 1 or 2
and m is 1, 2 or 3; and pharmaceutically acceptable acid addition
salts thereof with the exception of compounds, wherein A and B are
simultaneously a bond and Y is --CHR--; to a patient requiring such
treatment.
18. The process for preparing a compound of formula I according to
claim 1 wherein the process is reacting a secondary amine of
formula 55with an aldehyde or ketone of formula 56thereby forming a
compound of formula 57wherein Ar.sup.1, Ar.sup.2, Q, X, Y, R and B
have the significance given above.
19. The process for preparing a compound of formula I according to
claim 1 wherein the process is oxydizing a compound of formula 58to
a compound of formula 59and to a compound of formula 60wherein
Ar.sup.1, Ar.sup.2, X, A, Y and B have the significance given
above.
20. The process for preparing a compound of formula I according to
claim 1 wherein the process is reacting a secondary amine of
formula 61with a compound of formula 62thereby forming a compound
of formula 63wherein L is a leaving group, selected from the group
consisting of Cl, Br or p-toluenesulfonate and Ar.sup.1, Ar.sup.2,
Q, X, and wherein A, Y and B have the significance given above.
21. The process of forming a compound of formula I of claim 1
wherein the process is reacting a secondary amine of formula 64with
a compound of formula 65thereby forming a compound of formula
66wherein Ar.sup.1, Ar.sup.2, Q, X, Y and B have the significance
given above.
22. The process of preparing a compound of formula I of claim 1
wherein the process is reacting a secondary amine of formula 67with
an aldehyde of formula 68and with an alkyne of formula 69thereby
forming a compound of formula 70wherein Ar.sup.1, Ar.sup.2, Q, X, R
and B have the significance given above.
23. The process of forming a compound of formula I of claim 1
wherein the process is reacting a compound of formula 71with a
compound of formulaAr.sup.2halto give a compound of formula
72wherein Ar.sup.1, Ar.sup.2, Q, X and A have the significance
given above.
24. The process of forming a compound of formula I of claim 1
wherein the process is cleaving off a O-protecting group of
compounds of formula 73thereby forming a compound of formula
74wherein Ar.sup.1, Ar.sup.2, Q, X, A, Y and B have the
significance given above and P is a O-protecting group selected
from the group consisting of benzyl and a methoxymethyl group.
25. The process of forming a compound of formula I in claim 1
wherein the process is reducing a compound of formula 75to a
compound of formula 76wherein Ar.sup.1, Ar.sup.2, Q, X and B have
the significance given above.
26. The process of forming a compound of formula I of claim 1
wherein the process is reacting a compound of formula 77with a
compound of formula 78forming a compound of formula 79wherein
Ar.sup.1, Ar.sup.2, Q, X, A and B have the significance given
above
27. A pharmaceutical composition for modulating neuronal activity
and plasticity associated with NMDA receptor subtype selective
blockers comprising an effective amount of compound having the
structure of formula I 80wherein Ar.sup.1 is selected from the
group consisting of pyridyl and phenyl, pyridyl and phenyl
substituted by hydroxy, lower alkyl, halogen, amino, nitro,
benzyloxy or lower alkoxy-lower alkoxy, and the group 81wherein
Z.sup.1 is a five membered heterocyclic ring, which contains one or
two heteroatoms, selected from N or O; R.sup.1 is selected from
hydrogen, hydroxy and an oxo group; Ar.sup.2 is selected from the
group consisting of pyridyl and phenyl, pryridyl and phenyl
optionally substituted by hydroxy, lower alkyl, halogen, amino,
nitro, benzyloxy or lower alkoxy-lower alkoxy, and the group
82wherein Z.sup.2 is a five or six membered ring,, a five or six
membered ring which optionally contains one or two heteroatoms,
selected from N or O; and Q is --S--, --S(O)-- or --S(O).sub.2--; X
is a bond, --CH(OH)-- or --(CH.sub.2).sub.n--; A is a bond or
--(CHR).sub.m--; R is selected from hydrogen, halogen or hydroxy,
independently from each other if m is 2 or 3; Y is selected from
--(CR.sub.2).sub.m--, --O--, --C.dbd.C--, --C.ident.C--,
piperidin-1-yl, pyrrolidin-1-yl or C.sub.4-C.sub.6-cycloal- kyl,
and piperidin-2-yl, pyrrolidin-1-yl or C.sub.4-C.sub.6-cycloalkyl
rings substituted by hydroxy; B is a bond, --O-- or --(CHR).sub.m;
n is 1 or2; and m is 1, 2 or 3; and pharmaceutically acceptable
acid addition salts thereof with the exception of compounds,
wherein A and B are simultaneously a bond and Y is --CHR--, in a
pharmaceutically acceptable vehicle.
Description
FIELD OF INVENTION
[0001] The present invention is generally related to heterocyclic
compounds and more particularly to substituted heterocyclics useful
as NDMA receptor selective subtype blockers for modulation neuronal
activity and plasticity.
BACKGROUND
[0002] The present invention relates to compounds of the general
formula 4
[0003] wherein
[0004] Ar.sup.1 is pyridyl or phenyl, substituted by hydroxy, lower
alkyl, halogen, amino, nitro. benzyloxy or lower alkoxy-lower
alkoxy, or is the group 5
[0005] wherein Z.sup.1 is a five membered heterocyclic ring, which
contains one or two heteroatoms, selected from N or O;
[0006] R.sup.1 is hydrogen, hydroxy or an oxo group;
[0007] Ar.sup.2 is pyridyl or phenyl, optionally substituted by
hydroxy, lower alkyl, halogen, amino, nitro, benzyloxy or lower
alkoxy-lower alkoxy, or is the group 6
[0008] wherein Z.sup.2 is a five or six membered ring, which
optionally contains one or two heteroatoms, selected from N or O;
and
[0009] Q is --S--, --S(O)-- or --S(O).sub.2--;
[0010] X is a bond, --CH(OH)-- or --(CH.sub.2).sub.n--;
[0011] A is a bond or --(CHR).sub.m--;
[0012] R is hydrogen, halogen or hydroxy, independently from each
other if m is 2 or 3;
[0013] Y is --(CR.sub.2).sub.m--, --O--, --C.dbd.C--,
--C.ident.C--, piperidin-1-yl, pyrrolidin-1-yl or
C.sub.4-C.sub.6-cycloalkyl, which rings are optionally substituted
by hydroxy;
[0014] B is a bond, --O-- or --(CHR).sub.m;
[0015] n is 1 or 2; and
[0016] m is 1, 2 or3;
[0017] and to pharmaceutically acceptable acid addition salts
thereof.
[0018] Excluded from the scope of formula I are those compounds,
wherein A and B are simultaneously a bond and Y is --CHR--. These
compounds have been described in EP 160 436, useful as
antiarrhytmic agents.
[0019] The present invention embraces racemic mixtures and all
their corresponding enantiomers.
[0020] The compounds of formula I and their salts are distinguished
by valuable therapeutic properties. Compounds of the present
invention are NMDA (N-methyl-D-aspartate)-receptor subtype
selective blockers, which have a key function in modulating
neuronal activity and plasticity which makes them key players in
mediating processes underlying development of CNS as well as
learning and memory formation.
[0021] Under pathological conditions of acute and chronic forms of
neurodegeneration over-activation of NMDA receptors is a key event
for triggering neuronal cell death. NMDA receptors are composed of
members from two sub-unit families, namely NR-1 (8 different splice
variants) and NR-2 (A to D) originating from different genes.
Members from the two sub-unit families show a distinct distribution
in different brain areas. Heteromeric combinations of NR-1 members
with different NR-2 sub-units result in NMDA receptors displaying
different pharmaceutical properties. Possible therapeutic
indications for NMDA receptor subtype specific blockers include
acute forms of neurodegeneration caused, e.g., by stroke and brain
trauma, and chronic forms of neurodegeneration such as Alzheimer's
disease, Parkinson's disease, Huntington's disease, ALS
(amyotrophic lateral sclerosis) and neurodegeneration associated
with bacterial or viral infections, and, in addition, chronic and
acute pain.
[0022] Objects of the invention are the compounds of formula I and
pharmaceutically acceptable acid addition salts thereof, the
preparation of the compounds of formula I and salts thereof,
medicaments containing a compound of formula I or a
pharmaceutically acceptable acid addition salt thereof, the
manufacture of such medicaments and the use of the compounds of
formula I and their pharmaceutically acceptable salts in the
control or prevention of illnesses, especially of illnesses and
disorders of the kind referred to earlier, and, respectively, for
the manufacture of corresponding medicaments.
[0023] The following definitions of the general terms used in the
present description apply irrespective of whether the terms in
question appear alone or in combination.
[0024] As used herein, the term "lower alkyl" denotes a straight-
or branched-chain alkyl group containing from 1 to 7 carbon atoms,
for example, methyl, ethyl, propyl, isopropyl, butyl and the like.
Preferred are groups from 1 to 4 carbon atoms.
[0025] The term "halogen" denotes chlorine, iodine, fluorine and
bromine.
[0026] The term "lower alkoxy" denotes a group wherein the alkyl
residue is as defined above.
[0027] A "five membered heterocyclic ring, which contains one or
two heteroatoms, selected from N or O" denotes, for example,
oxazolyl, isoxazolyl, furyl, pyrrolyl, pyrrolidinyl, pyrrolinyl,
imidazolyl, imidazolidinyl, imidazolinyl, pyrazolyl, pyrazolidinyl
or pyrazolinyl.
[0028] A "five or six membered ring, which optionally contains one
or two heteroatoms, selected from N or O" are, for example;
cyclopentyl, cyclohexyl, oxazolyl, isoxazolyl, furyl, pyrrolyl,
pyrrolidinyl, pyrrolinyl, imidazolyl, imidazolidinyl, imidazolinyl,
pyrazolyl, pyrazolidinyl, pyrazolinyl, pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, piperidyl, piperazinyl or
morpholinyl.
[0029] The term "pharmaceutically acceptable acid addition salts"
embraces salts with inorganic and organic acids, such as
hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid,
citric acid, formic acid, fumaric acid, maleic acid, acetic acid,
succinic acid, tartaric acid, methane-sulfonic acid,
p-toluenesulfonic acid and the like.
[0030] Preferred compounds of formula I in the scope of the present
invention are those, wherein Ar.sup.1 is phenyl, substituted by
hydroxy, Q is --S--, Ar.sup.2 is phenyl and X is --CH.sub.2. These
are the following compounds:
[0031]
(S)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol,
[0032]
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol,
[0033]
(R)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol,
[0034] (2R, 3S) or (2S,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-y-
l-sulfanyl]-phenol,
[0035] (2S, 3S) or (2R,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-y-
l-sulfanyl]-phenol,
[0036]
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidin-3-yl-sulfanyl]-phenol,
[0037] (3RS, 3RS) and (3RS,
3SR)-4-[1-(3-hydroxy-4-phenyl-butyl)-pyrrolidi-
n-3-yl-sulfanyl]-phenol,
[0038] (2S, 3R) or (2R,
3R)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-y-
l-sulfanyl]-phenol,
[0039]
(2RS,3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-p-
henol or
[0040]
(2RS,3R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-p-
henol.
[0041] Compounds of the present invention, in which Ar.sup.1 is
phenyl, substituted by hydroxy, Q is --S(O)--, Ar.sup.2 is phenyl
and X is --CH.sub.2-- are further preferred, for example the
following compound:
[0042] (3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[1-(4-phenyl-butyl)-pyrro- lidine-3-sulfinyl]-phenol,
[0043] (2R,3R, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sul-
finyl]-phenol,
[0044] (2S,3S, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sul-
finyl]-phenol,
[0045] (2R,3S, S-oxide
R)-4-[1-(2-fuoro-4-phenyl-butyl)-pyrrolidine-3-sulf- inyl]-phenol
or
[0046] (3S, S-oxide S) or (3S, S-oxide
R)-4-[1-(2,2-difluoro-4-phenyl-buty-
l)-pyrrolidine-3-sulfinyl]-phenol.
[0047] Further preferred are compounds, in which Ar.sup.1 is
phenyl, substituted by hydroxy, Q is --S(O).sub.2--, Ar.sup.2 is
indanyl or phenyl, optionally substituted by methyl and X is
--CH.sub.2-- or --CH(OH)--, for example the following
compounds:
[0048]
(S)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
[0049]
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
[0050] (2R, 3S) and (2S,
3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3--
sulfonyl]-phenol,(3RS, cis) and (3RS,
trans)-4-[1-(3-benzyl-cyclobutyl)-py-
rrolidine-3-sulfonyl]-phenol,
[0051] (3RS,
cis)-4-[1-(4-phenyl-cyclohexyl)-pyrrolidine-3-sulfonyl]-pheno-
l,
[0052]
(3RS,4RS)-4-(4-hydroxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolid-
in-3-ol,
[0053]
(RS)-4-[1-(4-m-tolyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
[0054]
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidine-3-sulfonyl]-phenol,
[0055]
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol,
[0056]
(RS)-4-[1-(1-phenyl-piperidin-4-yl)-pyrrolidine-3-sulfonyl]-phenol
or
[0057] (2R, 3S) or (2S,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidine-3--
sulfonyl]-phenol.
[0058] The afore-mentioned compounds of formula I can be
manufactured in accordance with the invention by
[0059] a) reacting a secondary amine of formula 7
[0060] with an aldehyde or ketone of formula 8
[0061] to a compound of formula 9
[0062] wherein Ar.sup.1, Ar.sup.2, Q, X, Y, R and B have the
significance given above, or
[0063] b) oxydizing a compound of formula 10
[0064] to a compound of formula 11
[0065] and/or to a compound of formula 12
[0066] wherein Ar.sup.1, Ar.sup.2, X, A, Y and B have the
significance given above, or
[0067] c) reacting a secondary amine of formula 13
[0068] with a compound of formula 14
[0069] to give a compound of formula 15
[0070] wherein L is a leaving group, such as Cl, Br or
p-toluenesulfonate and Ar.sup.1, Ar.sup.2, Q, X, A, Y and B have
the significance given above, or
[0071] d) reacting a secondary amine of formula 16
[0072] with a compound of formula 17
[0073] to give a compound of formula 18
[0074] wherein Ar.sup.2, Ar.sup.2, Q, X, Y and B have the
significance given above, or
[0075] e) reacting a secondary amine of formula 19
[0076] with an aldehyde of formula 20
[0077] and with an alkyne of formula 21
[0078] to give a compound of formula 22
[0079] wherein Ar.sup.1, Ar.sup.2, Q, X, R and B have the
significance given above, or
[0080] f) reacting a compound of formula 23
[0081] with a compound of formula
Ar.sup.2hal
[0082] to give a compound of formula 24 25
[0083] wherein Ar.sup.1, Ar.sup.2, Q, X and A have the significance
given above, or
[0084] g) cleaving off a O-protecting group of compounds of formula
26
[0085] to obtain a compound of formula 27
[0086] wherein Ar.sup.1, Ar.sup.2, Q, X, A, Y and B have the
significance given above and P is a O-protecting group, for example
benzyl or a methoxymethyl group, or
[0087] h) reducing a compound of formula 28
[0088] to a compound of formula 29
[0089] wherein Ar.sup.1, Ar.sup.2, Q, X and B have the significance
given above; or
[0090] i) reacting a compound of formula 30
[0091] with a compound of formula 31
[0092] to obtain a compound of formula 32
[0093] wherein Ar.sup.1, Ar.sup.2, Q, X, A and B have the
significance given above; and
[0094] if desired, modifying one or more substituents within the
definitions given above, or if desired, converting the compound of
formula I obtained into a pharmaceutically acceptable salt.
[0095] In the following the preparation of compounds of formula I
are described in more detail: 33
[0096] wherein Ar.sup.1, Ar.sup.2, Q, Y, R and B have the
significance given above.
[0097] Compounds of formula I (A is --CHR--) can be prepared by
reacting a secondary amine of formula II with an aldehyde or ketone
of formula III in the presence of a reducing agent like
NaHB(OAc).sub.3 in conventional manner. 34
[0098] wherein Ar.sup.1, Ar.sup.2, X, A, Y, R and B have the
significance given above. The compound of formula I-4 (Q is
--SO.sub.2--) can be prepared by oxidation of compounds of formula
I-3 (Q is --SO--), which itself can be prepared by oxidation of
compounds of formula I-2 (Q is --S--), using oxone.RTM. as
oxidative agent. Oxone is a trade name for a stable oxidizing agent
formed from a mixture consisting of 2KHSO5.KHSO4.KSO4. The
oxidative agent and its use is described in Fieser and Fieser,
Reagents for Organic Synthesis, vol. 1, (1967). 35
[0099] Compounds of formula I can be prepared by reacting an amine
of formula II with an electrophile compound of formula IV, wherein
L is a leaving group like Cl, Br or p-toluenesulfonate and the
remaining substituents are described above. 36
[0100] wherein Ar.sup.1, Ar.sup.2, Q, X, Y and B have the
significance given above.
[0101] Compounds of formula I-5, wherein A is --CH.sub.2--CH(OH)--
can be prepared by reacting of an amine of formula II with an
epoxide of formula V in conventional manner. 37
[0102] wherein Ar.sup.1, Ar.sup.2, Q, X, R and B have the
significance given above.
[0103] Compounds of formula I-6, wherein A is --CHR-- and Y is
--C.ident.C-- can be prepared under Mannich conditions by reacting
an amine of compound of formula II with an aldehyde of formula VI
and an alkyne of formula VII. 38
[0104] wherein Ar.sup.1, Ar.sup.2, Q, X and A have the significance
given above.
[0105] Compounds of formula I-7, wherein Y is --CH.sub.2 and B is
--CH.sub.2-- can be prepared under Suzuki conditions by reacting an
alkene of formula VIII with Ar.sup.2hal, wherein hal is an halogene
like Br or I. 39
[0106] wherein Ar.sup.1, Ar.sup.2, Q, X and A have the significance
given above.
[0107] Alternatively, compounds of formula I-7, wherein Y is
--CH.sub.2-- and --B-- is --CH.sub.2-- can be prepared in two steps
under Heck conditions. Alkene compounds of formula VIII can react
with Ar.sup.2hal, wherein hal is an halogen like Br or I to provide
an alkene derivative of formula I-8 which can be subsequently
hydrogenated to obtain compounds of formula I-7. 40
[0108] wherein Ar.sup.1, Ar.sup.2, Q, X, A, Y and B have the
significance given above and P is a O-protecting group, which may
be, for example benzyl or methoxymethyl.
[0109] Compounds of formula I-9 or of compounds of formula I-10 can
be prepared by cleaving off an O-protecting group of compounds of
formulas X or XI. H.sub.2-Pd/C have been used to cleave a
benzylether and acidic conditions have been used to cleave a
methoxymethyl ether. 41
[0110] wherein Ar.sup.1, Ar.sup.2, Q, X and B have the significance
given above.
[0111] Compounds of formula I-11, wherein A is --CH.sub.2-- and Y
is --CH.sub.2CH(OH)-- can be prepared by reducing a ketone of
formula XII, which itself can be prepared by reacting an amine of
formula II with a Michael acceptor of formula XIII. 42
[0112] wherein Ar.sup.1, Ar.sup.2, Q, X, A and B have the
significance given above.
[0113] Compounds of formula I-12 and I-13 can be prepared by
reacting of an amine compound of formula XIV-1 or XIV-2 with
boronic acid of formula XV. 43
[0114] A compound of formula XIV-1 or of XIV-2 can be prepared by
treating the boc-protected amine compound of formula XVI-1 or XVI-2
with an acid, for example with trifluoroacetic acid. 44
[0115] A compound of formula II can be prepared by hydrogenolysis
of the benzylated amine of formula XVII, or by acidic hydrolysis of
either the boc-protected amine compound of formula XVIII or the
tosyl-protected amine compound of formula XIX. 45
[0116] Compounds of formulas XVII, XVIII and XIX, wherein Q is
--SO.sub.2--, can be prepared by oxidation of compounds,
respectively XVII, XVIII and XIX, wherein Q is --SO--, which
themselves can be prepared by oxidation of compounds, respectively
XVII, XVIII and XIX, wherein Q is --S--, using oxone or m-CPBA as
oxidative agent.
[0117] Compounds of formulas XVII, XVIII and XIX, wherein Q is
--S-- can be prepared by reaction of a thiol of formula XXIII with
respectively electrophiles of formulas XX, XXI and XXII, wherein L'
is a leaving group, such as p-toluenesulfonate or mesylate. 46
[0118] Alternatively, compounds of formula XVIII, wherein Q is
--S-- can be prepared by reacting a thiol of formula XXIV with
Ar.sup.1-hal in the presence of a catalytic amount of
Pd.sub.2(dba).sub.3 and DPPF.
[0119] Pd.sub.2(dba).sub.3 is tris(dibenzylideneacetone)dipalladium
and dppf is 1,1'-bis(diphenylphosphino)ferrocene. 47
[0120] The monofluoro sulfoxides are obtained by oxidation of the
corresponding sulfides with oxone. The sulfides are prepared by
reduction of the amides with borane dimethylsulfide complex. The
amides are accessible by coupling the racemic monofluoroacid with
the R or S configured pyrrolidines in the presence of an activating
agent like carbonyldimidazole. The racemic acid is prepared by
saponification of the corresponding racemic methyl ester. This
methyl ester as well as the R or S configured pyrrolidines have
been described in more detail in the working examples. 48
[0121] The difluoro sulfoxides are obtained by oxidation of the
corresponding sulfides with oxone. The sulfides are prepared from
the achiral difluoro alcohol after a Swern oxidation and reductive
amination in the presence of an R or S configured pyrrolidine and
sodium triacetoxyborohydride as reducing agent. The alcohol is
obtained from the commercially available ethyl 2-oxo
4-phenylbutyrate after treatment with DAST ((diethylamino)sulfur
trifluoride) and reduction with sodium borohydride.
[0122] The starting materials of formulas III, IV, V, VI, VII,
XIII, XV, XX, XXI, XXII, XXIII, XXVI and XXIX are commercial
products or can be prepared according to methods known per se.
[0123] Pharmaceutically acceptable salts can be manufactured
according to methods which are known per se and familiar to any
person skilled in the art. The acid addition salts of compounds of
formula I are especially well suited for pharmaceutical use.
[0124] In schemes 1-10 and 15 and 16 are described processes for
preparation of compounds of formula I, starting from known
compounds, from commercial products or from compounds, which can be
prepared in conventional manner. In schemes 11-14 are described
processes for the preparation of intermediates.
[0125] The preparation of compounds of formula I are described in
more detail in working examples 1-69.
[0126] As mentioned earlier, the compounds of formula I and their
pharmaceutically usable acid addition salts possess valuable
pharmacodynamic properties. They are NMDA-receptor subtype
selective blockers, which have a key function in modulating
neuronal activity and plasticity which makes them key players in
mediating processes underlying development of CNS as well as
learning and memory formation.
[0127] The compounds were investigated in accordance with the test
given hereinafter.
Test Method
3H-Ro 25-6981 binding (Ro 25-6981 is
[R-(R*,S*)]-a-(4-hydroxy-phenyl)-b-me-
thyl-4-(phenyl-methyl)-1-piperidine propanol)
[0128] Male Fuillinsdorf albino rats weighing between 150-200 g
were used. Membranes were prepared by homogenization of the whole
brain minus cerebellum and medulla oblongata with a Polytron
(10.000 rpm, 30 seconds), in 25 volumes of a cold Tris-HCl 50 mM,
EDTA 10 mM, pH 7.1 buffer. The homogenate was centrifuged at 48.000
g for 10 minutes at 4.degree. C. The pellet was resuspended using
the Polytron in the same volume of buffer and the homogenate was
incubated at 37.degree. C. for 10 minutes. After centrifugation the
pellet was homogenized in the same buffer and frozen at -80.degree.
C. for at least 16 hours but not more than 10 days. For the binding
assay the homogenate was thawed at 37.degree. C., centrifuged and
the pellet was washed three times as above in a Tris-HCl 5 mM, pH
7.4 cold buffer. The final pellet was resuspended in the same
buffer and used at a final concentration of 200 mg of
protein/ml.
[0129] 3H-Ro 25-6981 binding experiments were performed using a
Tris-HCl 50 mM, pH 7.4 buffer. For displacement experiments 5 nM of
3H-Ro 25-6981 were used and non-specific binding was measured ed
using 10 mM of tetrahydroisoquinoline and usually it accounts for
10% of the total. The incubation time was 2 hours at 4.degree. C.
and the assay was stopped by filtration on Whatman GF/B glass fiber
filters (Unifilter-96, Packard, Zurich, Switzerland). The filters
were washed 5 times with cold buffer. The radioactivity on the
filter was counted on a Packard Top-count microplate scintillation
counter after addition of 40 mL of microscint 40 (Canberra Packard
S.A., Zurich, Switzerland).
[0130] The effect of compounds were measured using a minimum of 8
concentrations and repeated at least once. The pooled normalized
values were analyzed using a non-linear regression calculation
program which provide IC.sub.50 with their relative upper and lower
95% confidence limits (RS1, BBN, USA).
[0131] The IC.sub.50 (.mu.M) of preferred compounds tested in
accordance with the above mentioned methods are in the range of
about 0.009-0.100.
[0132] Examples of some IC.sub.50 values of preferred compounds are
given in the table below:
1 Example IC.sub.50 (.mu.M) 2 0.009 3 0.02 35 0.029 43 0.031 4 0.04
6 0.059 62 0.06 68 0.077 16 0.08
[0133] The compounds of formula I and their salts, as herein
described, can be incorporated into standard pharmaceutical dosage
forms, for example, for oral or parenteral application with the
usual pharmaceutical adjuvant materials, for example, organic or
inorganic inert carrier materials, such as, water, gelatin,
lactose, starch, magnesium stearate, talc, vegetable oils, gums,
polyalkylene-glycols and the like. The pharmaceutical preparations
can be employed in a solid form, for example, as tablets,
suppositories, capsules, or in liquid form, for example, as
solutions, suspensions or emulsions. Pharmaceutical adjuvant
materials can be added and include preservatives stabilizers,
wetting or emulsifying agents, salts to change the osmotic pressure
or to act as buffers. The pharmaceutical preparations can also
contain other therapeutically active substances.
[0134] The dosage can vary within wide limits and will, of course,
be fitted to the individual requirements in each particular case.
In the case of oral administration the dosage lies in the range of
about 0.1 mg per dosage to about 1000 mg per day of a compound of
general formula I although the upper limit can also be exceeded
when this is shown to be indicated.
[0135] The following examples illustrate the present invention in
more detail. However, they are not intended to limit its scope in
any manner. All temperatures are given in degrees Celsius.
EXAMPLE 1
(RS)-4-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol
hydrochloride
[0136] (RS)-4-(Pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt (0.22 g, 0.65 mmol), 4-phenyl-butyraldehyde (0.096 g, 0.65
mmol), triethylamine (0.090 ml, 0.65 mmol), and sodium
triacetoxyborohydride (0.2 g, 0.97 mmol) were suspended in
1,2-dichloroethane (4 ml). After 3 hours stirring at room
temperature, the reaction mixture was quenched with saturated
NaHCO.sub.3 (10 ml). The aqueous phase was extracted with
CH.sub.2Cl.sub.2 (3 times). The combined organic phases were dried
over Na.sub.2SO.sub.4, filtered and the solvent was evaporated. The
residue was chromatographed over silica gel (CH.sub.2Cl.sub.2-MeOH,
19:1) to provide a white solid which was suspensed in MeOH.
HCl-Et.sub.2O was added to provide
(RS)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfonyl]-pheno- l
hydrochloride (0.180 g, 70%) as a white solid, m.p. 121-124.degree.
C. and MS: m/e=360.3 (M+H.sup.+).
[0137] 4-Phenyl-butyraldehyde is a known compound and has been
prepared as described in the following reference: S. M. Moosavi; R.
S. Beddoes; C. I. F. Watt; J. Chem. Soc. Perkin Trans. 2, 8, 1997,
1585-1596.
[0138] Following the general method of example 1 the compounds of
example 2 to example 17 were prepared.
EXAMPLE 2
(S)-4-[1-(4-Phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol
[0139] The title compound, MS: m/e=328.3 (M+H.sup.+) and
[.alpha.].sub.n.sup.20=-6.26.degree. (c=0.61, chloroform) was
prepared from (S)-4-(pyrrolidin-3-yl-sulfanyl)-phenol hydrobromide
and 4-phenyl-butyraldehyde.
EXAMPLE 3
(R)-4-[1-(4-Phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol
[0140] The title compound, MS: m/e=328.3 (M+H.sup.+) and
[.alpha.].sub.n.sup.20=+10.15.degree. (c=0.56, chloroform) was
prepared from (R)-4-(pyrrolidin-3-yl-sulfanyl)-phenol
trifluoroacetic acid salt and 4-phenyl-butyraldehyde.
EXAMPLE 4
(3RS, cis) and (3RS,
trans)-4-[1-(3-Benzyl-cyclobutyl)-pyrrolidine-3-sulfo-
nyl]-phenol
[0141] The title compound, MS: m/e=372.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and 3-benzyl-cyclobutanone.
EXAMPLE 5
(RS)-4-[1-(3-Phenyl-propyl)-pyrrolidin-3-yl-sulfanyl]-phenol
hydrochloride
[0142] The title compound, MS: m/e=314.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidin-3-yl-sulfanyl)-phenol hydrobromide and
3-phenylpropionaldehyde.
EXAMPLE 6
(3RS,
cis)-4-[1-(4-Phenyl-cyclohexyl)-pyrrolidine-3-sulfonyl]-1-phenol
[0143] The title compound, MS: m/e=386.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
and 4-phenylcyclohexanone.
EXAMPLE 7
(3RS,
trans)-4-[1-(4-Phenyl-cyclohexyl)-pyrrolidine-3-sulfonyl]-phenol
[0144] The title compound, MS: m/e=386.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
and 4-phenylcyclohexanone.
EXAMPLE 8
(RS)-4-[1-(3-Phenyl-propyl)-piperidin-3-yl-sulfanyl]-phenol
[0145] The title compound, MS: m/e=328.3 (M+H.sup.+) was prepared
from (RS)-4-(piperidin-3-yl-sulfanyl)-phenol hydrobromide and
3-phenylpropionaldehyde.
EXAMPLE 9
(RS)-5-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-1H-indazole
[0146] The title compound, MS: m/e=384.2(M+H.sup.+) was prepared
from (RS)-5-(pyrrolidine-3-sulfonyl)-1H-indazole trifluoroacetic
acid and 4-phenyl-butyraldehyde.
EXAMPLE 10
(RS)-4-[1-(2-Benzyloxy-ethyl)-pyrrolidine-3-sulfonyl]-phenol
[0147] The title compound, MS: m/e=362.2 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and benzyloxyacetaldehyde.
EXAMPLE 11
4-[1-(4-Phenyl-butyl)-azetidine-3-sulfonyl]-phenol
hydrochloride
[0148] The title compound, MS: m/e=346.3 (M+H.sup.+) was prepared
from 4-(azetidine-3-sulfonyl)-phenol and
4-phenyl-butyraldehyde.
EXAMPLE 12
(RS)-3-[1-(3-Phenyl-propyl)-pyrrolidin-3-yl-sulfanyl]-phenol
[0149] The title compound, MS: m/e=314.3 (M+H.sup.+) was prepared
from (RS)-3-(pyrrolidin-3-yl-sulfanyl)-phenol hydrochloride and
3-phenylpropionaldehyde.
EXAMPLE 13
(RS)-6-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-3H-benzooxazol-2-one
[0150] The title compound, MS: m/e=401.4 (M+H.sup.+) was prepared
from (RS)-6-(pyrrolidine-3-sulfonyl)-3H-benzooxazol-2-one
trifluoroacetic acid and 4-phenyl-butyraldehyde.
EXAMPLE 14
(RS)-5-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-1,3-dihydro-indol-2-one
[0151] The title compound, MS: m/e=399.4 (M+H.sup.+) was prepared
from (RS)-5-(pyrrolidine-3-sulfonyl)-1,3-dihydro-indol-2-one
trifluoroacetic acid and 4-phenyl-butyraldehyde.
EXAMPLE 15
(RS)-4-[1-(4-Phenyl-butyl)-piperidin-3-yl-sulfanyl]-phenol
[0152] The title compound, MS: m/e=342.3 (M+H.sup.+) was prepared
from (RS)-4-(piperidin-3-yl-sulfanyl)-phenol hydrobromide and
4-phenyl-butyraldehyde.
EXAMPLE 16
(3RS,4RS)-4-(4-Hydroxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolidin-3-ol
[0153] The title compound, MS: m/e=376.3 (M+H.sup.+) was prepared
from (3RS,4RS)-4-(4-hydroxy-benzenesulfonyl)-pyrrolidin-3-ol and
4-phenyl-butyraldehyde.
EXAMPLE 17
(RS)-4-[1-(4-Phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol
hydrochloride
[0154] The title compound, MS: m/e=328.2 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidin-3-yl-sulfanyl)-phenol hydrobromide and
4-phenyl-butyraldehyde.
EXAMPLE 18
(3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[1-(4-Phenyl-butyl)-pyrrolidine-- 3-sulfinyl]-phenol
hydrochloride
[0155] (RS)-4-[1-(4-Phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol
(0.15 g, 0.46 mmol) was dissolved in MeOH (4 ml), cooled to
0.degree. C. and treated with oxone (0.28 g, 0.46 mmol). After 1
hour stirring at 0.degree. C., the reaction mixture was quenched
with saturated NaHCO.sub.3 (15 ml). The aqueous phase was extracted
with CH.sub.2Cl.sub.2 (3 times). The combined organic phases were
dried over Na.sub.2SO.sub.4, filtered and the solvent was
evaporated. The residue was chromatographed over silica gel (ethyl
acetate then ethyl acetate-MeOH, 95:5 then 9:1) to provide an oil
which was suspensed in MeOH. HCl-Et.sub.2O was added to provide
(3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[1-(4-phenyl-butyl)-pyrrolidine-3-sulfinyl]-phenol
hydrochloride (0.04 g, 23%) as a foam, MS: m/e=344.2
(M+H.sup.+).
[0156] Following the general method of example 18 the compounds of
example 19 to example 30 were prepared.
EXAMPLE 19
(S)-4-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol
[0157] The title compound, MS: m/e=360.3 (M+H.sup.+) and
[.alpha.].sub.n.sup.20=+2.62.degree. (c=0.534, chloroform) was
prepared from
(S)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol.
EXAMPLE 20
(R)-4-[1-(4-Phenyl-butyl)-pyrrolidine-3-sulfonyl]-phenol
hydrochloride
[0158] The title compound, MS: m/e=360.3 (M+H.sup.+) was prepared
from
(R)-4-[1-(4-phenyl-butyl)-pyrrolidin-3-yl-sulfanyl]-phenol.
EXAMPLE 21
(RS)-4-[1-(3-Phenyl-propyl)-pyrrolidine-3-sulfonyl]-phenol
hydrochloride
[0159] The title compound, MS: m/e=346.4 (M+H.sup.+) was prepared
from
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidin-3-yl-sulfanyl]-phenol.
EXAMPLE 22
(2R, 3S) or (2S,
3S)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidine-3-sulfony-
l]-phenol
[0160] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from (2R, 3S) or (2S,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulf-
anyl]-phenol.
EXAMPLE 23
(2S, 3S) or (2R,
3S)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidine-3-sulfony-
l]-phenol
[0161] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from (2S, 3S) or (2R,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulf-
anyl]-phenol.
EXAMPLE 24
(2R, 3R) or (2S,
3R)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidine-3-sulfony-
l]-phenol
[0162] The title compound, MS: m/e=376.3 (M+H.sup.+) was prepared
from (2R, 3R) or (2S,
3R)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulf-
anyl]-phenol.
EXAMPLE 25
(2S, 3R) or (2R,
3R)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidine-3-sulfony-
l]-phenol
[0163] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from (2S, 3R) or (2R,
3R)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulf-
anyl]-phenol.
EXAMPLE 26
(3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[1-(3-Phenyl-propyl)-piperidine-- 3-sulfinyl]-phenol
hydrochloride
[0164] The title compound, MS: m/e=344.4 (M+H.sup.+) was prepared
from
(RS)-4-[1-(3-phenyl-propyl)-piperidin-3-yl-sulfanyl]-phenol.
EXAMPLE 27
(RS)-4-[1-(3-Phenyl-propyl)-piperidine-3-sulfonyl]-phenol
hydrochloride
[0165] The title compound, MS: m/e=360.3 (M+H.sup.+) was prepared
from
(RS)-4-[1-(3-phenyl-propyl)-piperidin-3-yl-sulfanyl]-phenol.
EXAMPLE 28
(RS)-4-[1-(4-Phenyl-butyl)-piperidine-3-sulfonyl]-phenol
hydrochloride
[0166] The title compound, MS: m/e=374.4 (M+H.sup.+) was prepared
from
(RS)-4-[1-(4-phenyl-butyl)-piperidin-3-yl-sulfanyl]-phenol.
EXAMPLE 29
(3RS, S-oxide RS) and (3RS, S-oxide
SR)-4-[1-(3-Phenyl-propyl)-pyrrolidine- -3-sulfinyl]-phenol
hydrochloride
[0167] The title compound, MS: m/e=330.4 (M+H.sup.+) was prepared
from
(RS)-4-[1-(3-phenyl-propyl)-pyrrolidin-3-yl-sulfanyl]-phenol.
EXAMPLE 30
(3RS, 3RS) and (3RS,
3SR)-4-[1-(3-Hydroxy-4-phenyl-butyl)-pyrrolidine-3-su-
lfonyl]-phenol
[0168] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from (3RS, 3RS) and (3RS,
3SR)-4-[1-(3-hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-
-sulfanyl]-phenol.
EXAMPLE 31
[0169]
(RS)-4-[1-(3-Phenoxy-propyl)-pyrrolidine-3-sulfonyl]-phenol(RS)-4-(-
pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid salt (0.2 g,
0.585 mmol), 3-phenoxypropylbromide (0.137 g, 0.64 mmol), and
NaHCO.sub.3 (0.1 g, 1.23 mmol) were suspended in acetonitrile (1.5
ml). After 24 hours stirring at 55.degree. C., the reaction mixture
was cooled to room temperature and quenched with saturated
NaHCO.sub.3. The aqueous phase was extracted with CH.sub.2Cl.sub.2
(3 times). The combined organic phases were washed with H.sub.2O,
dried over Na.sub.2SO.sub.4 and the solvent was evaporated. The
residue was chromatographed over silica gel (CH.sub.2Cl.sub.2-MeOH,
19:1) to provide (RS)-4-[1-(3-phenoxy-propyl)-pyr-
rolidine-3-sulfonyl]-phenol (0.16 g, 75%) as a white foam, MS:
m/e=362.2 (M+H.sup.+).
[0170] Following the general method of example 31 the compounds of
example 32 to example 38 were prepared.
EXAMPLE 32
(RS)-4-[1-(2-Indan-2-yl-ethyl)-pyrrolidine-3-sulfonyl]-phenol
[0171] The title compound, MS: m/e=372.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and toluene-4-sulfonic acid 2-indan-2-yl-ethyl ester.
Toluene-4-sulfonic acid 2-indan-2-yl-ethyl ester is a known
compound and has been prepared as described in U.S. Pat. No.
3,984,407.
EXAMPLE 33
(RS)-2-{2-[3-(4-Hydroxy-benzenesulfonyl)-pyrrolidin-1-yl]-ethyl}-indan-2-o-
l hydrochloride
[0172] The title compound, MS: m/e=388.2 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and toluene-4-sulfonic acid 2-(2-hydroxy-indan-2-yl)-ethyl
ester.
EXAMPLE 34
(RS)-4-[1-(5-Phenyl-pentyl)-pyrrolidine-3-sulfonyl]-phenol
[0173] The title compound, MS: m/e=374.4 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and (5-bromo-pentyl)-benzene. (5-Bromo-pentyl)-benzene is a
known compound and has been prepared as described in the following
reference: J. Thomas; W. Marlow; J. Med. Chem.; 6; 1963;
107-111.
EXAMPLE 35
(2R, 3S) and (2S,
3S)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfony-
l]-phenol
[0174] The title compound, MS: m/e=378.3 (M+H.sup.+) was prepared
from (S)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and (RS)-toluene-4-sulfonic acid 2-fluoro-4-phenyl-butyl
ester.
EXAMPLE 36
(2RS, 3RS) and (2RS,
3SR)-2-{2-[3-(4-Hydroxy-benzenesulfonyl)-pyrrolidin-1-
-yl]-ethyl}-1,2,3,4-tetrahydro-naphthalen-2-ol
[0175] The title compound, MS: m/e=402.4 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and
(RS)-2-(2-bromo-ethyl)-1,2,3,4-tetrahydro-naphthalen-2-ol.
EXAMPLE 37
(RS)-4-[1-(4-Phenyl-but-3-ynyl)-pyrrolidine-3-sulfonyl]-phenol
[0176] The title compound, MS: m/e=355.1 (M.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and toluene-4-sulfonic acid 4-phenyl-but-3-ynyl ester.
EXAMPLE 38
(RS)-4-{1-[2-(1,3-Dihydro-isoindol-2-yl)-ethyl]-pyrrolidine-3-sulfonyl)-ph-
enol hydrochloride
[0177] The title compound, MS: m/e=373.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
salt and 2-(2-chloro-ethyl)-2,3-dihydro-1H-isoindole.
2-(2-Chloro-ethyl)-2,3-dihyd- ro-1H-isoindole is a known compound
and has been prepared as described in the following reference: G.
Shoeb; J. Pharm. Sci.; 51; 1962; 469-471.
EXAMPLE 39
(2R, 3S) or (2S,
3S)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidin-3-ylsulfan-
yl]-phenol
[0178] see Example 40.
EXAMPLE 40
[0179] (2S, 3S) or (2R,
3S)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidin-3-y-
l-sulfanyl]-phenol(S)-4-(pyrrolidin-3-yl-sulfanyl)-phenol
hydrobromide (1 g, 3.6 mmol), (RS)-2-phenethyl-oxirane (0.8 g, 5.4
mmol) and triethylamine (0.76 ml, 5.4 mmol) were suspended in MeOH
(20 ml). After 4 hours refluxing, the reaction mixture was cooled
to room temperature and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 1:1 then 1:4)
to provide (2R, 3S) or (2S,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol
(0.1 g, first fraction, 8%) as a colorless oil (Example 39) MS:
m/e=344.4 (M+H.sup.+) and (2S, 3S) or (2R,
3S)-4-[1-(2-hydroxy-4-phenyl-butyl)-pyrr-
olidin-3-ylsulfanyl]-phenol (0.13 g, second fraction, 10%) as a
colorless oil (Example 40) MS: m/e=344.3
(M+H.sup.+).(RS)-2-Phenethyl-oxirane is a known compound and has
been prepared as described in the following reference: S. Levy;
Bull. Soc. Chim. Fr.; 49; 1931; 1823-1826.
[0180] Following the general method of examples 39 and 40,
compounds of example 41 to example 46 were prepared.
EXAMPLE 41
(2S, 3R) or (2R,
3R)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulfa-
nyl]-phenol
[0181] The title compound, MS: m/e=344.4 (M+H.sup.+) was prepared
from (R)-4-(pyrrolidin-3-yl-sulfanyl)-phenol trifluoro-acetic acid
and (RS)-2-phenethyl-oxirane.
EXAMPLE 42
(2R, 3R) or (2S
3R)-4-[1-(2-Hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl-sulfan-
yl]-phenol
[0182] The title compound, MS: m/e=344.4 (M+H.sup.+) was prepared
from (R)-4-(pyrrolidin-3-yl--sulfanyl)-phenol trifluoro-acetic acid
and (RS)-2-phenethyl-oxirane.
EXAMPLE 43
(2R, 3S) and (2S,
3S)-4-[1-(2-Hydroxy-2-indan-2-yl-ethyl)-pyrrolidine-3-su-
lfonyl]-phenol
[0183] The title compound, MS: m/e=388.3 (M+H.sup.+) was prepared
from (S)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid and
(RS)-2-indan-2-yl-oxirane.
EXAMPLE 44
(2RS, 3RS) and (2RS
3SR)-4-[1-(2-Hydroxy-4-phenyl-butyl)-piperidin-3-yl-su-
lfanyl]-phenol
[0184] The title compound, MS: m/e=358.2 (M+H.sup.+) was prepared
from (RS)-4-(piperidin-3-yl-sulfanyl)-phenol hydrobromide and
(RS)-2-phenethyl-oxirane.
EXAMPLE 45
(3S, cis) or (3 S,
trans)-4-[1-(1-Hydroxy-3-phenyl-cyclobutylmethyl)-pyrro-
lidine-3-sulfonyl]-phenol
[0185] The title compound, MS: m/e=388.3 (M+H.sup.+) was prepared
from (S)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid and
cis or trans-5-phenyl-1-oxa-spiro[2.3]hexane.
EXAMPLE 46
(3S, trans) or (3S,
cis)-4-[1-(1-Hydroxy-3-phenyl-cyclobutylmethyl)-pyrrol-
idine-3-sulfonyl]-phenol
[0186] The title compound, MS: m/e=388.2 (M+H.sup.+) was prepared
from (S)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid and
trans or cis-5-phenyl-1-oxa-spiro[2.3]hexane.
EXAMPLE 47
(RS)-4-[1-(4-Phenyl-but-2-ynyl)-pyrrolidine-3-sulfonyl]-phenol
[0187] (RS)-4-(Pyrrolidine-3-sulfonyl)-phenol trifluoro-acetic acid
(0.2 g, 0.59 mmol) and NaHCO.sub.3 (74 mg, 0.88 mmol) were
suspended in MeOH (2 ml). After 10 minutes, reaction mixture was
concentrated. The residue was taken up in CHCl.sub.3. The resulting
solid was filtered and the filtrate was concentrated. The
so-obtained foam was dissolved in dioxane (2 ml) and treated
successively with paraformaldehyde (17.6 mg, 0.586 mmol),
3-phenyl-1-propyne (68 mg, 0.586 mmol) and CuCl (6.2 mg, 0.062
mmol). The reaction mixture was stirred at 100.degree. C. for 0.75
hour then cooled to room temperature and concentrated. The residue
was treated with saturated NaHCO.sub.3. The aqueous phase was
extracted with CH.sub.2Cl.sub.2 (3 times). The combined organic
phases were dried over Na.sub.2SO.sub.4, filtered and the solvent
was evaporated. The residue was chromatographed over silica gel
(CH.sub.2Cl.sub.2-MeOH 19:1) to provide
(RS)-4-[1-(4-phenyl-but-2-ynyl)-pyrrolidine-3-sulfonyl]-phenol
(0.14 g, 69%) as an orange foam, MS: m/e=356.3 (M+H.sup.+).
EXAMPLE 48
(RS)-4-[1-(4-m-Tolyl-butyl)-pyrrolidine-3-sulfonyl]-phenol
[0188] To a 0.degree. C. solution of
(RS)-4-(1-but-3-enyl-pyrrolidine-3-su- lfonyl)-phenol (0.106 g,
0.378 mmol) in THF (0.5 ml), 9-BBN (1.66 ml, 0.74 ml, 0.5 M
solution in THF) was added dropwise. The reaction mixture was
allowed to warm up slowly to room temperature. After 4 hours
stirring, the reaction mixture was treated successively with DMF
(1.5 ml), 3-bromotoluene (0.046 ml, 0.377 mmol),
PdCl.sub.2(dppf).sub.2-dichloromet- hane complex (9.3 mg, 0.01
mmol), and K.sub.2CO.sub.3 (95 mg, 0.69 mmol). After 5 hours
stirring at 60.degree. C., the reaction mixture was cooled to room
temperature, quenched with ethylacetate and H.sub.2O. The aqueous
phase was extracted with ethylacetate. The combined organic phases
were washed with H.sub.2O, dried over Na.sub.2SO.sub.4, filtered
and concentrated. The residue was chromatographed over silica gel
(CH.sub.2Cl.sub.2-MeOH, 98:2) to provide
(RS)-4-[1-(4-m-tolyl-butyl)-pyrr- olidine-3-sulfonyl]-phenol (66
mg, 47%) as a light yellow foam, MS: m/e=374.4 (M+H.sup.+).
[0189] Following the general method of example 48 the compounds of
example 49 to example 50 were prepared.
EXAMPLE 49
(RS)-4-{1-[4-(2-Methoxymethoxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phen-
ol
[0190] The title compound, MS: m/e=420.3 (M+H.sup.+) was prepared
from (RS)-4-(1-but-3-enyl-pyrrolidine-3-sulfonyl)-phenol and
1-iodo-2-methoxymethoxy-benzene. 1-Iodo-2-methoxymethoxy-benzene is
a known compound and has been prepared as described in the
following reference: J. R. Labrosse; C. Poncet; P. Lhoste; D.
Sinou; Tetrahedron:, Asymmetry; 10; 6; 1999; 1069-1078
EXAMPLE 50
(RS)-4-{1-[4-(3-Benzyloxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol
[0191] The title compound, MS: m/e=464.3 (M-H.sup.+) was prepared
from (RS)-4-(1-but-3-enyl-pyrrolidine-3-sulfonyl)-phenol and
benzyl-(3-iodo-phenyl)-ether. Benzyl-(3-iodo-phenyl)-ether is a
known compound and has been prepared as described in the following
reference: W. Kipping; J. Chem. Soc.; 1957; 3246-3250
EXAMPLE 51
(RS)-4-{1-[4-(3-Hydroxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol
[0192]
(RS)-4-{1-[4-(3-Benzyloxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-ph-
enol (88.4 mg, 0.2 mmol) and Pd/C (40 mg, 10% Pd on charcoal) in
MeOH (5 ml) were refluxed for 2 hours under an atmospheric pressure
of hydrogen. The reaction mixture was then cooled to room
temperature, the catalyst was filtered and the filtrate was
concentrated. The residue was chromatographed over silica gel
(CH.sub.2Cl.sub.2-MeOH, 19:1) to provide
(RS)-4-{1-[4-(3-hydroxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol
(53 mg, 69%) as a light beige solid, MS: m/e=376.3 (M+H.sup.+).
[0193] Following the general method of example 51 the compounds of
example 52 to example 54 were prepared.
EXAMPLE 52
(RS)-4-{1-[4-(4-Hydroxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol
[0194] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from
(RS)-4-{1-[4-(4-benzyloxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol.
EXAMPLE 53
(RS)-(4-Pyridin-3-yl-butyl)-pyrrolidine-3-sulfonyl]-phenol
[0195] The title compound, MS: m/e=361.2 (M+H.sup.+) was prepared
from
(RS)-4-[1-(4-pyridin-3-yl-but-3-enyl)-pyrrolidine-3-sulfonyl]-phenol.
EXAMPLE 54
(3RS,
4SR)-4-(4-Hydroxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolidin-3-o-
l
[0196] The title compound, MS: m/e=376.4 (M+H.sup.+) was prepared
from (3RS,
4SR)-4-(4-benzyloxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolidin--
3-ol.
EXAMPLE 55
(RS)-4-{1-[4-(2-Hydroxy-phenyl)-butyl]-pyrrolidine-3-sulfonyl}-phenol
[0197]
(RS)-4-{1-[4-(2-Methoxymethoxy-phenyl)-butyl]-pyrrolidine-3-sulfony-
l}-phenol (34 mg, 0.08 mmol) in iPrOH (1 ml) was treated with
HCl/Et.sub.2O (1 ml). After 45 hours stirring at room temperature,
the reaction mixture was quenched with saturated NaHCO.sub.3. The
aqueous phase was extracted with CH.sub.2Cl.sub.2. The combined
organic phases were dried over Na.sub.2SO.sub.4, filtered and the
solvent was evaporated. The residue was chromatographed over silica
gel (CH.sub.2Cl.sub.2-MeOH, 19:1) to provide
(RS)-4-{1-[4-(2-hydroxy-phenyl)--
butyl]-pyrrolidine-3-sulfonyl}-phenol (17 mg, 56%) as a beige foam,
MS: m/e=376.4 (M+H.sup.+).
EXAMPLE 56
(3RS, 3RS) and (3RS,
3SR)-4-[1-(3-Hydroxy-4-phenyl-butyl)-pyrrolidin-3-yl--
sulfanyl]-phenol
[0198]
(RS)-4-[3-(4-Hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-1-phenyl-buta-
n-2-one (200 mg, 0.6 mmol) in MeOH (3 ml) was treated with
NaBH.sub.4 (33.2 mg, 0.9 mmol). After 15 minutes stirring at room
temperature, the reaction mixture was acidified to pH 3 with 1N HCl
then adjusted to pH 8 with saturated NaHCO.sub.3. The aqueous phase
was extracted with CH.sub.2Cl.sub.2. The combined organic phases
were dried over Na.sub.2SO.sub.4, filtered and the solvent was
evaporated. The residue was chromatographed over silica gel
(ethylacetate) to provide (3RS, 3RS) and (3RS,
3SR)-4-[1-(3-hydroxy-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-p-
henol (187 mg, 93%) as a white foam, MS: m/e=344.3 (M+H.sup.+).
EXAMPLE 57
(RS)-4-[1-(1-Phenyl-piperidin-4-yl)-pyrrolidine-3-sulfonyl]-phenol
[0199] (RS)-4-(1-Piperidin-4-yl-pyrrolidine-3-sulfonyl)-phenol
trifluoroacetic acid (53.8 mg, 0.1 mmol), Et.sub.3N (50.5 mg, 0.5
mmol), phenylboronic acid (36.6 mg, 0.3 mmol) and copper(II)
acetate (36 mg, 0.2 mmol) were suspensed in CH.sub.2Cl.sub.2 (2
ml). After 3.5 hours stirring at room temperature, the reaction
mixture was directly chromatographed over silica gel
(CH.sub.2Cl.sub.2-MeOH 98:2 then 95:5) to provide
(RS)-4-[1-(1-phenyl-piperidin-4-yl)-pyrrolidine-3-sulfonyl]-phenol
(10 mg, 26%) as a white foam, MS: m/e=387.3 (M+H.sup.+).
EXAMPLE 58
(2R,3R, S-oxide
R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]--
phenol
[0200]
(2RS,3R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-ph-
enol (0.56 g, 1.62 mmol) was dissolved in MeOH (50 ml), cooled to
0.degree. C. and treated with oxone (0.5 g, 0.81 mmol). After 4
hours stirring at 0.degree. C., reaction mixture was quenched with
saturated NaHCO.sub.3 (65 ml). Aqueous phase was extracted with
CH.sub.2Cl.sub.2 (6 times). Combined organic phases were dried over
Na.sub.2SO.sub.4 and the solvent was evaporated. The residue was
chromatographed by MPLC over silica gel (CH.sub.2Cl.sub.2-MeOH,
99:1 then 98:2) then by preparative HPLC (EtOH-heptane, 08:92,
detection at 254 nm) to provide (2R,3R, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]-phenol
(30 mg, first fraction, 5%), MS: m/e =362.2 (M+H.sup.+).
EXAMPLE 59
(2S,3R, S-oxide
R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]--
phenol
[0201] The title compound was prepared in accordance with example
58 to provide (2S,3R, S-oxide
R)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-s- ulfinyl]-phenol
(27 mg, second fraction, 4.7%), MS: m/e=362.2 (M+H.sup.+).
EXAMPLE 60
(2RS,3R, S-oxide
S)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]- -phenol
hydrochloride
[0202] The title compound was prepared in accordance with example
58 to provide (2RS,3R, S-oxide
S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidine-3-- sulfinyl]-phenol
hydrochloride (100 mg, third fraction, 17%), MS: m/e=362.2
(M+H.sup.+).
[0203] Following the general method of examples 58-60, the
compounds of example 61 to 63 were prepared.
EXAMPLE 61
(2RS,3S, S-oxide
S)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]- -phenol
hydrochloride
[0204] The title compound, MS: m/e=362.2 (M+H.sup.+) was prepared
from
(2RS,3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 62
(2S,3S, S-oxide
R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]--
phenol
[0205] The title compound, MS: m/e=362.2 (M+H.sup.+) was prepared
from
(2RS,3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 63
(2R,3S, S-oxide
R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidine-3-sulfinyl]--
phenol
[0206] The title compound, MS: m/e=362.2 (M+H.sup.+) was prepared
from
(2RS,3S)-4-[1-(2-fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 64
(3S, S-oxide R) or (3S, S-oxide
S)-4-[1-(2.2-Difluoro-4-phenyl-butyl)-pyrr-
olidine-3-sulfinyl]-phenol
[0207]
(3S)-4-[1-(2,2-Difluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-ph-
enol (0.25 g, 0.688 mmol) was dissolved in MeOH (20 ml), cooled to
0.degree. C. and treated with oxone (0.21 g, 0.34 mmol). After 4
hours stirring at 0.degree. C., reaction mixture was quenched with
saturated NaHCO.sub.3 (65 ml). Aqueous phase was extracted with
CH.sub.2Cl.sub.2 (3 times). Combined organic phases were dried over
Na.sub.2SO.sub.4 and the solvent was evaporated. The residue was
chromatographed by MPLC over silica gel (hexane-ethyl acetate, 98:2
to 50:50) to provide (3S, S-oxide R) or (3S, S-oxide
S)-4-[1-(2,2-difluoro-4-phenyl-butyl)-pyrrolidine-3-su-
lfinyl]-phenol (140 mg, first fraction, 54%), MS: m/e=380.4
(M+H.sup.+).
EXAMPLE 65
(3S, S-oxide S) or (3S, S-oxide
R)-4-[1-(2.2-Difluoro-4-phenyl-butyl)-pyrr-
olidine-3-sulfinyl]-phenol
[0208] The title compound was prepared in accordance with example
64 to provide (3S, S-oxide S) or (3S, S-oxide
R)-4-[1-(2,2-difluoro-4-phenyl-bu-
tyl)-pyrrolidine-3-sulfinyl]-phenol (72 m(g, second fraction, 28%),
MS: m/e=380.4 (M+H.sup.+). Following the general method of example
64 and 65, the compounds of example 66 and 67 were prepared.
EXAMPLE 66
(3R, S-oxide R) or (3R, S-oxide
S)-4-[1-(2,2-Difluoro-4-phenyl-butyl)-pyrr-
olidine-3-sulfinyl]-phenol
[0209] The title compound, MS: m/e=380.3 (M+H.sup.+) was prepared
from
(3R)-4-[1-(2,2-difluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 67
(3R, S-oxide S) or (3R, S-oxide
R)-4-[1-(2,2-Difluoro-4-phenyl-butyl)-pyrr-
olidine-3-sulfinyl]-phenol
[0210] The title compound, MS: m/e=380.3 (M+H.sup.+) was prepared
from
(3R)-4-[1-(2,2-difluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 68
(2RS,3
S)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0211] (2RS,3
S)-2-Fluoro-1-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-
-4-phenyl-butan-1-one (200 mg, 0.56 mmol) was dissolved in THF (4
ml). Borane-dimethylsulfide complex (170 .mu.l, 1.67 mmol) was
added. The mixture was refluxed for 7 hours and then cooled to
0.degree. C. MeOH (0.7 ml) was added dropwise and the solvent was
removed in vacuo. The residue was dissolved with THF (3.5 ml) and
5N HCl (1.1 ml) and was stirred at 60.degree. C. for 12 hours. The
solvent was removed in vacuo and the residue was taken up in
saturated NaHCO.sub.3 (3 ml).The aqueous layer was extracted with
CH.sub.2Cl.sub.2 (3 times).The combined organic phases were dried
over Na.sub.2SO.sub.4, filtered and the solvent was evaporated. The
residue was chromatographed over silica gel (CH.sub.2Cl.sub.2-MeOH,
99:1) to provide (2RS,3S)-4-[1-(2-fluoro-4-phenyl-
-butyl)-pyrrolidin-3-ylsulfanyl]-phenol (134 mg, 70%) as colorless
oil, MS: m/e=346.3 (M+H.sup.+).
[0212] Following the general method of example 68 the compound of
example 69 was prepared.
EXAMPLE 69
(2RS,3R)-4-[1-(2-Fluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0213] The title compound, MS: m/e=346.3 (M+H.sup.+) was prepared
from
(2RS,3R)-2-fluoro-1-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-4-phen-
yl-butan-1-one.
Synthesis of Intermediates
EXAMPLE 70
(RS)-4-[3-(4-Hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-1-phenyl-butan-2-one
[0214] (RS)-4-(Pyrrolidin-3-ylsulfanyl)-phenol hydrobromide (470
mg, 1.7 mmol), Et.sub.3N (0.35 ml, 2.5 mmol) and
1-phenyl-3-buten-2-one (0.25 g, 1.7 mmol) were suspended in
CH.sub.2Cl.sub.2 (10 ml). After stirring overnight at room
temperature, the reaction mixture was concentrated and
chromatographed over silica gel (hexane-ethylacetate 1:1 then
ethylacetate) to provide
(RS)-4-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin--
1-yl]-1-phenyl-butan-2-one (90 mg, 16%) as a brown oil, MS:
m/e=342.2 (M+H.sup.+).
[0215] 1-Phenyl-3-buten-2-one is a known compound and has been
prepared as described in the following reference: E. Negishi; V.
Bagheri; S. Chatterjee; M. Fen-Tair; J. A. Miller; T. A. Stoll;
Tetrahedron Lett.; 24; 47; 1983; 5181-5184.
EXAMPLE 71
(RS)-4-(1-But-3-enyl-pyrrolidine-3-sulfonyl)-phenol
[0216] The title compound, MS: m/e=282.1 (M+H.sup.+), has been
prepared according to the procedure described for example 31 from
(RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid salt
and 4-bromo-butene.
EXAMPLE 72
(3RS,
4SR)-4-(4-Benzyloxy-benzenesulfonyl)-1-(4-phenyl-butyl)-pyrrolidin-3-
-ol
[0217] The title compound, MS: m/e=466.3 (M+H.sup.+), has been
prepared according to the procedure described for example 1, from
(3RS, 4SR)-4-(4-benzyloxy-benzenesulfonyl)-pyrrolidin-3-ol
trifluoro-acetic acid and 4-phenyl-butyraldehyde.
EXAMPLE 73
(RS)-4-[1-(4-Pyridin-3-yl-but-3-enyl)-pyrrolidine-3-sulfonyl]-phenol
[0218] (RS)-4-(1-But-3-enyl-pyrrolidine-3-sulfonyl)-phenol (100 mg,
0.355 mmol), 3-bromopyridine (62 mg, 0.39 mmol),
PdCl.sub.2(dppf).sub.2-dichlor- omethane complex (9.3 mg, 0.01
mmol), and K.sub.2CO.sub.3 (95 mg, 0.69 mmol) were suspended in DMF
(1.5 ml). After 5 hours stirring at 80.degree. C., the reaction
mixture was cooled to room temperature and concentrated. The
residue was chromatographed over silica gel (CH.sub.2Cl.sub.2/MeOH
97:3 then 19/1) to provide (RS)-4-[1-(4-pyridin-3--
yl-but-3-enyl)-pyrrolidine-3-sulfonyl]-phenol (100 mg, 78%) as a
light orange foam, MS: m/e=359.2 (M+H.sup.+).
EXAMPLE 74
(RS)-4-(Pyrrolidin-3-ylsulfanyl)-phenol hydrobromide
[0219]
(RS)-4-[1-(Toluene-4-sulfonyl)-pyrrolidin-3-ylsulfanyl]-phenol (1.9
g, 5.44 mmol) in phenol (5.1 g, 54.4 mmol) was treated with HBr (25
ml, 48%). After 4 hours stirring at 100.degree. C., the reaction
mixture was cooled to room temperature and quenched with H.sub.2O
and CH.sub.2Cl.sub.2. The aqueous phase was washed with
CH.sub.2Cl.sub.2 and concentrated to provide
(RS)-4-(pyrrolidin-3-ylsulfanyl)-phenol hydrobromide (1.13 g, 75%)
as a brown oil, MS: m/e=196.2 (M+H.sup.+). Following the general
method of example 74, the compounds of example 75 to example 77
were prepared.
EXAMPLE 75
(S)-4-(Pyrrolidin-3-ylsulfanyl)-phenol hydrobromide
[0220] The title compound, MS: m/e=196.2 (M+H.sup.+) and
[.alpha.].sub.n.sup.20=-20.41 (c=1.02, MeOH) was prepared from
(S)-4-[1-(toluene-4-sulfonyl)-pyrrolidin-3-ylsulfanyl]-phenol.
EXAMPLE 76
(RS)-4-(Piperidin-3-ylsulfanyl)-phenol hydrobromide
[0221] The title compound, MS: m/e=210.3 (M+H.sup.+) was prepared
from
(RS)-4-[1-(toluene-4-sulfonyl)-piperidin-3-ylsulfanyl]-phenol.
EXAMPLE 77
(RS)-3-(Pyrrolidin-3-ylsulfanyl)-phenol hydrochloride
[0222] The title compound, MS: m/e=196.2 (M+H.sup.+) was prepared
from
(RS)-3-(3-methoxy-phenylsulfanyl)-1-(toluene-4-sulfonyl)-pyrrolidine.
EXAMPLE 78
(R)-4-(Pyrrolidin-3-ylsulfanyl)-phenol trifluoroacetic acid
[0223] (R)-3-(4-Hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester (3.0 g, 10.2 mmol) in CH.sub.2Cl.sub.2 (36
ml) was treated with trifluoroacetic acid (7.8 ml, 0.1 mol). After
1 hour stirring at room temperature, the reaction mixture was
concentrated to provide (R)-4-(pyrrolidin-3-yl-sulfanyl)-phenol
trifluoroacetic acid (3.46 g) as an orange oil, MS: m/e=196.2
(M+H.sup.+) and [.alpha.].sub.n.sup.20+25.06.degree. (c=1.2,
MeOH).
[0224] Following the general method of example 78 the compounds of
example 79 to example 86 were prepared.
EXAMPLE 79
(RS)-4-(Pyrrolidine-3-sulfonyl)-phenol trifluoro acetic acid
[0225] The title compound, MS: m/e=228.1 (M+H.sup.+) was prepared
from (RS)-3-(4-hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester.
EXAMPLE 80
(S)-4-(Pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
[0226] The title compound, MS: m/e=228.1 (M+H.sup.+) and
[.alpha.].sub.n.sup.20=-3.45.degree. (c=0.99, MeOH) was prepared
from (S)-3-(4-hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester.
EXAMPLE 81
(3RS, 4RS)-4-(4-Hydroxy-benzenesulfonyl)-pyrrolidin-3-ol
[0227] The title compound, MS: m/e=244.2 (M+H.sup.+) was prepared
from
3-hydroxy-4-(4-hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester.
EXAMPLE 82
(3RS, 4SR)-4-(4-Benzyloxy-benzenesulfonyl)-pyrrolidin-3-ol
trifluoroacetic acid
[0228] The title compound, MS: m/e=334.2 (M+H.sup.+) was prepared
from (3RS,
4SR)-3-(4-benzyloxy-benzenesulfonyl)-4-hydroxy-pyrrolidine-1-carbox-
ylic acid tert-butyl ester.
EXAMPLE 83
(RS)-5-(Pyrrolidine-3-sulfonyl)-1H-indazole trifluoroacetic
acid
[0229] The title compound, MS: m/e=252.2 (M+H.sup.+) was prepared
from
(RS)-5-(1-tert-butoxycarbonyl-pyrrolidine-3-sulfonyl)-indazole-1-carboxyl-
ic acid tert-butyl ester.
EXAMPLE 84
(RS)-5-(Pyrrolidine-3-sulfonyl)-1,3-dihydro-indol-2-one
trifluoroacetic acid
[0230] The title compound, MS: m/e=267.0 (M+H.sup.+) was prepared
from
(RS)-3-(2-oxo-2,3-dihydro-1H-indole-5-sulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester.
EXAMPLE 85
(RS)-6-(Pyrrolidine-3-sulfonyl)-3H-benzooxazol-2-one
trifluoroacetic acid
[0231] The title compound, MS: m/e=269.2 (M+H.sup.+) was prepared
from
(RS)-3-(2-oxo-3-trityl-2,3-dihydro-benzooxazole-6-sulfonyl)-pyrrolidine-1-
-carboxylic acid tert-butyl ester.
EXAMPLE 86
(RS)-4-(1-Piperidin-4-yl-pyrrolidine-3-sulfonyl)-phenol
trifluoroacetic acid
[0232] The title compound, MS: m/e=311.3 (M+H.sup.+) was prepared
from
(RS)-4-[3-(4-hydroxy-benzenesulfonyl)-pyrrolidin-1-yl]-piperidine-1-carbo-
xylic acid tert-butyl ester.
EXAMPLE 87
4-(Azetidine-3-sulfonyl)-phenol
[0233] The title compound, MS: m/e=214.2 (M+H.sup.+) was prepared
from 4-(1-benzhydryl-azetidine-3-sulfonyl)-phenol following the
procedure described for example 51.
EXAMPLE 88
(RS)-3-(4-Hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0234] (RS)-3-(4-Hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester (1.95 g, 6.6 mmol) was dissolved in MeOH (30
ml) and treated with oxone.RTM. (6.10 g, 9.9 mmol). After 3.5 hours
stirring at room temperature, the reaction mixture was filtered and
the filtrate was neutralized with saturated NaHCO.sub.3. The
aqueous phase was extracted with CH.sub.2Cl.sub.2 (3 times). The
combined organic phases were dried over Na.sub.2SO.sub.4, filtered
and the solvent was evaporated. The residue was chromatographed
over silica gel (hexane-ethyl acetate 4:1 then 1:1) to provide
(RS)-3-(4-hydroxy-benzenesulfonyl)-pyrrolidine-1-car- boxylic acid
tert-butyl ester (1.27 g, 58.8%) as a white foam, MS: m/e=328.2
(M+H.sup.+).
[0235] Following the general method of example 88 the compounds of
example 89 to example 91 were prepared
EXAMPLE 89
(S)-3-(4-Hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0236] The title compound, MS: m/e=326.3 (M-H.sup.+) and
[.alpha.].sub.n.sup.20=-25.72.degree. (c=1.07, chloroform) was
prepared from
(S)-3-(4-hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
EXAMPLE 90
(3RS
4RS)-3-Hydroxy-4-(4-hydroxy-benzenesulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester
[0237] The title compound, MS: m/e=344.4 (M-H.sup.+) was prepared
from (3RS,
4RS)-3-hydroxy-4-(4-hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxyli-
c acid tert-butyl ester.
EXAMPLE 91
4-(1-Benzhydryl-azetidine-3-sulfonyl)-phenol
[0238] The title compound, MS: m/e=380.3 (M+H.sup.+) was prepared
from 4-(1-benzhydryl-azetidin-3-ylsulfanyl)-phenol.
EXAMPLE 92
(RS)-5-(1-tert-Butoxycarbonyl-pyrrolidine-3-sulfonyl)-indazole-1-carboxyli-
c acid tert-butyl ester
[0239]
(RS)-5-(1-tert-Butoxycarbonyl-pyrrolidin-3-ylsulfanyl)-indazole-1-c-
arboxylic acid tert-butyl ester (0.175 g, 0.41 mmol) was dissolved
in CH.sub.2Cl.sub.2 (10 ml), cooled to 0.degree. C. and treated
with m-CPBA (0.26 g, 1.04 mmol, 70% of peracid). After 1 hour
stirring at 0.degree. C., the reaction mixture was quenched with
saturated NaHCO.sub.3. The organic phase was washed with saturated
NaHCO.sub.3, dried over Na.sub.2SO.sub.4, filtered and the solvent
was evaporated. The residue was chromatographed over silica gel
(hexane-ethyl acetate 9:1 then 4:1 then 2:1) to provide (RS)-5
-(1-tert-butoxycarbonyl-pyrrolidine-3-sulfony-
l)-indazole-1-carboxylic acid tert-butyl ester (0.127 g, 67.4%) as
a white foam, MS: m/e=452.3 (M+H.sup.+).
[0240] Following the general method of example 92 the compounds of
example 93 to example 94 were prepared.
EXAMPLE 93
(RS)-3-(2-Oxo-3-trityl-2,3-dihydro-benzooxazole-6-sulfonyl)-pyrrolidine-1--
carboxylic acid tert-butyl ester
[0241] The title compound, MS: m/e=628.1 (M+NH.sub.4.sup.+) was
prepared from
(RS)-3-(2-oxo-3-trityl-2,3-dihydro-benzooxazol-6-yl-sulfanyl)-pyrrol-
idine-1-carboxylic acid tert-butyl.
EXAMPLE 94
(RS)-3-(2-Oxo-2,3-dihydro-1H-indole-5-sulfonyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester
[0242] The title compound, MS: m/e=384.2 (M+NH.sub.4.sup.+) was
prepared from
(RS)-3-(2-oxo-2,3-dihydro-1H-indol-5-yl-sulfanyl)-pyrrolidine-1-carb-
oxylic acid tert-butyl ester.
EXAMPLE 95
(3RS,
4SR)-3-(4-Benzyloxy-benzenesulfonyl)-4-hydroxy-pyrrolidine-1-carboxy-
lic acid tert-butyl ester
[0243]
(RS)-3-(4-Benzyloxy-benzenesulfonyl)-4-oxo-pyrrolidine-1-carboxylic
acid tert-butyl ester (13.4 mg, 0.031 mmol) was dissolved in MeOH
(0.5 ml), cooled to 0.degree. C. and treated with NaBH.sub.4 (1.64
mg, 0.043 mmol). After 0.5 hour stirring at 0.degree. C., the
reaction mixture was acidified to pH 1 with 1N HCl. The aqueous
phase was extracted With CH.sub.2Cl.sub.2. The combined organic
phases were washed with H.sub.2O, dried over Na.sub.2SO.sub.4,
filtered and the solvent was evaporated to provide (3RS,
4SR)-3-(4-benzyloxy-benzenesulfonyl)-4-hydroxy-pyrrolidine--
1-carboxylic acid tert-butyl ester (12.3 mg, 92%) as a white solid,
MS: m/e=434.4 (M+H.sup.+).
EXAMPLE 96
(RS)-3-(4-Benzyloxy-benzenesulfonyl)-4-oxo-pyrrolidine-1-carboxylic
acid tert-butyl ester
[0244] (3RS,
4RS)-3-(4-Benzyloxy-benzenesulfonyl)-4-hydroxy-pyrrolidine-1--
carboxylic acid tert-butyl ester (50 mg, 0.1 mmol) was dissolved in
CH.sub.2Cl.sub.2 (2 ml) and treated successively with 4 .ANG.
molecular sieves (56 mg, powder) and pyridinium dichromate (56.4
mg, 0.15 mmol). After 3 hours stirring at room temperature, the
reaction mixture was directly chromatographed over silica gel
(hexane-ethyl acetate 4:1 then 1:1) to provide
(RS)-3-(4-benzyloxy-benzenesulfonyl)-4-oxo-pyrrolidine-1--
carboxylic acid tert-butyl ester (27 mg, 48%) as an oil, MS:
m/e=374.2 (M-tbutyl).
EXAMPLE 97
(3RS,
4RS)-3-(4-Benzyloxy-benzenesulfonyl)-4-hydroxy-pyrrolidine-1-carboxy-
lic acid tert-butyl ester
[0245] The title compound, MS: m/e=434.3 (M+H.sup.+) was prepared
from (3RS,
4RS)-3-(4-benzyloxy-phenylsulfanyl)-4-hydroxy-pyrrolidine-1-carboxy-
lic acid tert-butyl ester following the procedure described for
example 88.
EXAMPLE 98
(3RS,
4RS)-3-(4-Benzyloxy-phenylsulfanyl)-4-hydroxy-pyrrolidine-1-carboxyl-
ic acid tert-butyl ester
[0246] (3RS,
4RS)-3-Hydroxy-4-(4-hydroxy-phenylsulfanyl)-pyrrolidine-1-car-
boxylic acid tert-butyl ester (0.2 g, 0.6 mmol) was dissolved in
acetone (5 ml), and treated with K.sub.2CO.sub.3 (0.1 g, 0.7 mmol).
After 1 hour refluxing, the reaction mixture was cooled to room
temperature and benzylbromide (0.084 ml, 0.7 mmol) was added.
Reaction mixture was refluxed for an additional 3 hours then cooled
to room temperature and quenched with H.sub.2O. The aqueous phase
was extracted with CH.sub.2Cl.sub.2, the combined organic phases
were dried over Na.sub.2SO.sub.4, filtered and the solvent was
evaporated. The residue was chromatographed over silica gel
(hexane-ethyl acetate 2:1) to provide (3RS,
4RS)-3-(4-benzyloxy-phenylsulfanyl)-4-hydroxy-pyrrolidine-1-carboxy-
lic acid tert-butyl ester (0.208 g, 81%) as a yellow oil, MS:
m/e=402.4 (M+H.sup.+).
EXAMPLE 99
(RS)-4-[3-(4-Hydroxy-benzenesulfonyl)-pyrrolidin-1-yl]-piperidine-1-carbox-
ylic acid tert-butyl ester
[0247] The title compound, MS: m/e=411.3 (M+H.sup.+) was prepared
from (RS)-4-(pyrrolidine-3-sulfonyl)-phenol trifluoroacetic acid
and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester following
the procedure described for example 1.
EXAMPLE 100
(RS)-3-(4-Hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0248] (RS)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester (0.8 g, 2.34 mmol), 4-mercaptophenol (0.49 g, 3.88
mmol, 90%) and Na.sub.2CO.sub.3 (0.37 g, 3.51 mmol) were suspended
in acetonitrile (10 ml). After 20 hours refluxing, reaction mixture
was concentrated. The residue was taken up in H.sub.2O (15 ml) and
extracted with CH.sub.2Cl.sub.2 (3 times). The combined organic
phases were dried over Na.sub.2SO.sub.4, filtered and the solvent
was evaporated. The residue was chromatographed over silica gel
(hexane-ethylacetate 4:1 then 2:1) to provide
(RS)-3-(4-hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxyli- c acid
tert-butyl ester (0.56 g, 81%) as a slightly yellow solid, MS:
m/e=296.4
(M+H.sup.+).(RS)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carbox-
ylic acid tert-butyl ester is a known compound and has been
prepared as described in WO 9734895
[0249] Following the general method of example 100, the compounds
of example 101 to example 108 were prepared.
EXAMPLE 101
(R)-3-(4-Hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0250] The title compound, MS: m/e=295.1 (M.sup.+) and
[.alpha.].sub.n.sup.20+20.09.degree. (c=0.61, chloroform) was
prepared from
(S)-3-(toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester.
EXAMPLE 102
(S)-3-(4-Hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0251] The title compound, MS: m/e=294.3 (M-H.sup.+) and
[.alpha.].sub.n.sup.20=-18.43.degree. (c=0.52, chloroform) was
prepared from
(R)-3-(toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester.
(R)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester is a known compound and has been prepared as
described in the following reference: U. Nagel; H. G. Nedden; Chem.
Ber., Recl.; 130; 3; 1997; 385-398.
EXAMPLE 103
(3RS,
4RS)-3-Hydroxy-4-(4-hydroxy-phenylsulfanyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester
[0252] The title compound, MS: m/e=312.2 (M+H.sup.+) was prepared
from 6-oxa-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl
ester.
[0253] 6-Oxa-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid
tert-butyl ester is a known compound and has been prepared as
described in the following reference: C. Y. Hong,; Y. K. Kim; Y. H.
Lee; J. H. Kwak; Bioorg. Med. Chem. Lett.; 8; 3; 1998; 221-226
EXAMPLE 104
4-(1-Benzhydryl-azetidin-3-ylsulfanyl)-phenol
[0254] The title compound, MS: m/e=348.4 (M+H.sup.+) was prepared
from methanesulfonic acid 1-benzhydryl-azetidin-3-yl ester by using
DMF as solvent instead of acetonitrile. Methanesulfonic acid
1-benzhydryl-azetidin-3-yl ester is a known compound and has been
prepared as described in the following reference: N. I. Carruthers;
S. Wong; T. Chan; J. Chem. Res. Synop.; 9; 1996; 430-431.
EXAMPLE 105
(S)-4-[1-(Toluene-4-sulfonyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0255] The title compound, MS: m/e=349.1 (M.sup.+) and
[.alpha.].sub.n.sup.20=-41.41.degree. (c=1.10, chloroform) was
prepared from (R)-toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-pyrrolidin-3-yl ester by using DMF as
solvent instead of acetonitrile.
[0256] (R)-Toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-pyrrolidin-3-yl ester is a known compound
and has been prepared as described in the following reference: A.
Corruble; J. Y. Valnot; J. Maddaluno; P. Duhamel; J. Org. Chem.;
Vol. 63; 23; 8274
EXAMPLE 106
(RS)-4-[1-(Toluene-4-sulfonyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0257] The title compound, MS: m/e=349.1 (M.sup.+) was prepared
(from (RS)-toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-pyrrolidin-3-yl ester by using DMF as
solvent instead of acetonitrile. (RS)-Toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-pyrrolidin-3-yl ester is a known compound
and has been prepared as described in the following reference: J.
R. Shanklin; C. P. Johnson; A. G. Proakis; R. J. Barrett; J. Med.
Chem.; 1991; 34; 10; 301 1-3022
EXAMPLE 107
(RS)-4-[1-(Toluene-4-sulfonyl)-piperidin-3-ylsulfanyl]-phenol
[0258] The title compound, MS: m/e=363.0 (M.sup.+) was prepared
from (RS)-toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-piperidin-3-yl ester by using DMF as solvent
instead of acetonitrile. (RS)-Toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-piperidin-3-yl ester is a known compound and
has been prepared as described in the following reference: J. R.
Shanklin; C. P. Johnson; A. G. Proakis; R. J. Barrett; J. Med.
Chem.; 1991; 34; 10; 3011-3022
EXAMPLE 108
(RS)-3-(3-Methoxy-phenylsulfanyl)-1-(toluene-4-sulfonyl)-pyrrolidine
[0259] The title compound, MS: m/e=363.1 (M.sup.+) was prepared
from (RS)-toluene-4-sulfonic acid
1-(toluene-4-sulfonyl)-pyrrolidin-3-yl ester and
3-methoxythiophenol and by using DMF as solvent instead of
acetonitrile.
EXAMPLE 109
(S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0260] To a 0.degree. C. solution of
(S)-3-hydroxy-pyrrolidine-1-carboxyli- c acid tert-butyl ester (8.5
g, 45.4 mmol), triethylamine (9.47 ml, 68.1 mmol) and
dimethylaminopyridine (0.55 g, 4.5 mmol) in CH.sub.2Cl.sub.2 (150
ml) was added portionwise p-toluenesulfonyl chloride (9.52 g, 49.9
mmol). After 48 hours stirring at room temperature, reaction
mixture was acidified to pH 1 with 1N HCl and aqueous phase was
extracted with CH.sub.2Cl.sub.2. Combined organic phases were
washed with 1N HCl and H.sub.2O, dried over Na.sub.2SO.sub.4 and
concentrated. The residue was chromatographed over silica gel
(hexane-ethylacetate 9:1 then 8:2 then 1:1) to provide
(S)-3-(toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid
tert-butyl ester (13.1 g, 87%) as a slightly yellow oil, MS:
m/e=268.1 (M-OtBu) and [.alpha.].sub.n.sup.20=+17.55.degree.
(c=3.33, diethylether).
[0261] (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester
is a known compound and has been prepared as described in the
following reference: U. Nagel; H. G. Nedden; Chem. Ber.; Recl.;
130; 3; 1997; 385-398
[0262] Following the general method of example 109, the compounds
of example 110 to example 111 were prepared.
EXAMPLE 110
(RS)-Toluene-4-sulfonic acid 2-fluoro-4-phenyl-butyl ester
[0263] The title compound, MS: m/e=322.1 (M.sup.+) was prepared
from (RS)-2-fluoro-4-phenyl-butan-1-ol.
EXAMPLE 111
Toluene-4-sulfonic acid 2-(2-hydroxy-indan-2-yl)-ethyl ester
[0264] The title compound, MS: m/e=355.2 (M+Na.sup.+) was prepared
from 2-(2-hydroxy-ethyl)-indan-2-ol.
EXAMPLE 112
(RS)-2-(2-Bromo-ethyl)-1,2,3,4-tetrahydro-naphthalen-2-ol
[0265] To a 0.degree. C. solution of triphenylphosphine (1.03 g,
3.93 mmol), in CH.sub.2Cl.sub.2 (15 ml) was added slowly a solution
of bromine (0.192 ml, 3.74 mmol) in CH.sub.2Cl.sub.2. After 1 hour
stirring at room temperature, the reaction mixture was cooled to
0.degree. C. and treated slowly with a solution of
(RS)-2-(2-hydroxy-ethyl)-1,2,3,4-tetrahydro-nap- hthalen-2-ol (0.72
g, 3.74 mmol) in CH.sub.2Cl.sub.2 (15 ml). After 1.5 hour stirring
at room temperature, the reaction mixture was again cooled to
0.degree. C., treated slowly with triethylamine (0.52 ml, 3.74
mmol), washed successively with H.sub.2O and brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 9:1) to
provide (RS)-2-(2-bromo-ethyl)-1,2,3,4-t- etrahydro-naphthalen-2-ol
(0.58 g, 61%) as a colorless oil, MS: m/e=255.1 (M.sup.+).
EXAMPLE 113
(RS)-2-Fluoro-4-phenyl-butan-1-ol
[0266] To a 0.degree. C. suspension of LiAlH.sub.4 (0.4 g, 10.6
mmol) in dry THF (5 ml) was added dropwise a solution of
(RS)-2-fluoro-4-phenyl-bu- tyric acid methyl ester (1 g, 5.3 mmol)
in dry THF (10 ml). After 1 hour stirring at 0.degree. C., the
reaction mixture was quenched successively with H.sub.2O (0.4 ml),
5N NaOH (0.4 ml) and again H.sub.2O (1.2 ml). The resulting solid
was filtered and the filtrate was concentrated to provide
(RS)-2-fluoro-4-phenyl-butan-1-ol (0.89 g, 99%) as a colorless oil,
MS: m/e=168.1 (M.sup.+).
[0267] Following the general method of example 113, the compounds
of example 114 to example 115 were prepared.
EXAMPLE 114
2-(2-Hydroxy-ethyl)-indan-2-ol
[0268] The title compound, MS: m/e=178.1 (M.sup.+) was prepared
from (2-hydroxy-indan-2-yl)-acetic acid methyl ester.
[0269] (2-Hydroxy-indan-2-yl)-acetic acid methyl ester is a known
compound and has been prepared as described in the following
reference: H. R. Veen; H. Cerfontain; Can. J. Chem.; 62; 1984;
2202-2205.
EXAMPLE 115
(RS)-2-(2-Hydroxy-ethyl)-1,2,3,4-tetrahydro-naphthalen-2-ol
[0270] The title compound, MS: m/e=192.3 (M.sup.+) was prepared
from (RS)-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic
acid methyl ester.
[0271] (RS)-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic
acid methyl ester is a known compound and has been prepared as
described in the following reference: H. R. Veen: H. Cerfontain;
Can. J. Chem.; 62; 1984; 2202-2205.
EXAMPLE 116
(RS)-5-(1-tert-Butoxycarbonyl-pyrrolidin-3-yl-sulfanyl)-indazole-1-carboxy-
lic acid tert-butyl ester
[0272] To a room temperature solution of
(RS)-3-(1H-indazol-5-ylsulfanyl)-- pyrrolidine-1-carboxylic acid
tert-butyl ester (0.2 g, 0.61 mmol), and dimethylaminopyridine (7.4
mg,, 0.06 mmol) in CH.sub.2Cl.sub.2 (3 ml) was added slowly a
solution of di-tert-butyl dicarbonate (0.13 g, 0.61 mmol) in
CH.sub.2Cl.sub.2. After 30 minutes stirring at room temperature,
the reaction mixture was washed with H.sub.2O, dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 9:1 then 8:2)
to provide (RS)-5-(1-tert-butoxyca-
rbonyl-pyrrolidin-3-ylsulfanyl)-indazole-1-carboxylic acid
tert-butyl ester (0.19 g, 74%) as a yellow oil, MS: m/e=420.4
(M+H.sup.+).
EXAMPLE 117
(RS)-3-(2-Oxo-3-trityl-2,3-dihydro-benzooxazol-6-yl-sulfanyl)-pyrrolidine--
1-carboxylic acid tert-butyl ester
[0273] Tris(dibenzylideneacetone)dipalladium chloroform complex (14
mg, 13.5 .quadrature.mol) and 1,1'-bis(diphenylphosphino)ferrocene
(30 mg, 54.1 .quadrature.mol) in degassed and dry toluene (2 ml)
were stirred at room temperature until the solution turned orange
(15 minutes). 6-Bromo-3-trityl-3H-benzooxazol-2-one (0.2 g, 0.44
mmol), Cs.sub.2CO.sub.3 (0.22 g, 0.68 mmol) and
(RS)-3-mercapto-pyrrolidine-1-ca- rboxylic acid tert-butyl ester
(0.1 g, 0.49 mmol) in toluene (0.5 ml) were successively added.
After 4 hours stirring at 100.degree. C., the reaction mixture was
cooled to room temperature and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 9:1 then 1:1)
to provide
(RS)-3-(2-oxo-3-trityl-2,3-dihydro-benzooxazol-6-yl-sulfa-
nyl)-pyrrolidine-1-carboxylic acid tert-butyl ester (0.19 g. 77%)
as a white foam, MS: m/e=596.1 (M+NH.sub.4.sup.+).
[0274] Following the general method of example 117 the compounds of
example 118 to example 119 were prepared.
EXAMPLE 118
(RS)-3-(1H-Indazol-5-yl-sulfanyl)-pyrrolidine-1-carboxylic acid
tert-butyl ester
[0275] The title compound, MS: m/e=319.1 (M.sup.+) was prepared
from 5-iodo-1H-indazole. 5-Iodo-1H-indazole is a known compound and
has been prepared as described in the following reference: L.
Auwers; Chem. Ber.; 55; 1922; 1172.
EXAMPLE 119
(RS)-3-(2-Oxo-2,3-dihydro-1H-indol-5-yl-sulfanyl)-pyrrolidine-1-carboxylic
acid tert-butyl ester
[0276] The title compound, MS: m/e=334.4 (M.sup.+) was prepared
from 5-iodo-1,3-dihydro-indol-2-one.
EXAMPLE 120
5-Iodo-1,3-dihydro-indol-2-one
[0277] A solution of 2-indolinone (2.66 g, 20 mmol) in acetic acid
(20 ml) was stirred at room temperature in the presence of
N-iodosuccinimide (5.4 g, 24 mmol) for 2 hours. H.sub.2O (150 ml)
was then added. The precipitate was filtered, washed with H.sub.2O,
and dried. The resulting, solid was refluxed in ethyl acetate (50
ml), cooled to 0.degree. C., filtered, washed with ethylacetate and
ether and dried to provide 5-iodo-1,3-dihydro-indol-2-one (3.62 g.
70%) as a beige solid, m.p. 190-192.degree. C. and MS: m/e=259
(M.sup.+).
EXAMPLE 121
6-Bromo-3-trityl-3 H-benzooxazol-2-one
[0278] 6-Bromo-3H-benzooxazol-2-one (0.165 g, 0.77 mmol) was added
portionwise into a 0.degree. C. suspension of NaH (44.8 mg, 1 mmol,
55%) in dry DMF (4 ml). After 1 hour stirring at room temperature,
a solution of triphenylmethylchloride (0.24 g, 0.85 mmol) in DMF
(0.5 ml) was added. The reaction mixture was stirred 1 hour at room
temperature then quenched with H.sub.2O (15 ml). The aqueous phase
was extracted with ethyl acetate, the combined organic phases were
washed with H.sub.2O and brine, dried over Na.sub.2SO.sub.4 and
concentrated to provide 6-bromo-3-trityl-3H-benzooxazol-2-one (0.27
g, 77%) as a beige solid, MS: Mm/e=457.1 (M+H.sup.+).
[0279] 6-Bromo-3H-benzooxazol-2-one is a known compound and has
been prepared as described in the following reference: H. Gershon;
D. D. Clarke; M. Gershon; Monatsh. Chem.; 1993; 124; 4; 367-379
EXAMPLE 122
(RS)-2-Fluoro-4-phenyl-butyric acid methyl ester
[0280] nBuLi (13.8 ml, 22 mmol, 1.6 M in hexane) was added dropwise
into a 0.degree. C. solution of diisopropylamine (3.39 ml, 24 mmol)
in THF (34 ml). The reaction mixture was stirred at 0.degree. C.
for 15 minutes then cooled to -75.degree. C. and treated slowly
with a solution of methyl 4-phenylbutyrate (3.56 g, 20 mmol) in THF
(10 ml). After 30 minutes stirring at -75.degree. C.,
trimethylchlorosilane (5.06 ml, 40 mmol) was added dropwise and the
reaction mixture was allowed to warm up to room temperature. After
30 minutes, reaction mixture was concentrated, the residue was
taken up in CH.sub.2Cl.sub.2 (100 ml), the resulting precipitate
was filtered, filtrate was cooled to 13.degree. C. and subsequently
treated slowly with a solution of N-fluorodibenzenesulfonimi- de
(6.3 g, 20 mmol) in CH.sub.2Cl.sub.2 (50 ml). After 3 hours
stirring at room temperature, the reaction mixture was washed with
H.sub.2O (2 times). The aqueous phase was extracted with
CH.sub.2Cl.sub.2, the combined organic phases were dried over
Na.sub.2SO.sub.4 and concentrated. The residue was chromatographed
over silica gel (hexane-ethylacetate 99:1 then 98:2) to provide
(RS)-2-fluoro-4-phenyl-bu- tyric acid methyl ester (2.47 g, 63%) as
a colorless oil, MS: m/e=196.1 (M.sup.+).
[0281] Methyl 4-phenylbutyrate is a known compound and has been
prepared as described in the following reference: M. V. Bhatt; M.
Ravindranathan; V. Somayaji; G. V. Rao; J. Org. Chem; 49; 17; 1984;
3170-3173.
EXAMPLE 123
(RS)-3-Mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester
[0282] To a 0.degree. C. solution of
(RS)-3-acetylsulfanyl-pyrrolidine-1-c- arboxylic acid tert-butyl
ester (1.4 g, 5.07 mmol) in MeOH (15 ml) was added dropwise a
suspension of sodium methoxide (0.61 g, 11.3 mmol) in MeOH. After 6
hours stirring at room temperature, the reaction mixture was
neutralized with 1N HCl and MeOH was partially evaporated. H.sub.2O
and ethylacetate were added. The aqueous phase was extracted with
ethylacetate, the combined organic phases were washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated to provide
(RS)-3-mercapto-pyrrolidine-1-carboxylic acid tert-butyl ester (1.2
g, 100%) as a colorless oil, MS: m/e=130.1 (M-OtBu).
EXAMPLE 124
(RS)-3-Acetylsulfanyl-pyrrolidine-1-carboxylic acid tert-butyl
ester
[0283] To a 0.degree. C. solution of triphenylphosphine (2.1 g, 8
mmol) in THF (14 ml) was added dropwise (15 minutes)
diisopropylazodicarboxylate (1.55 ml, 8 mmol). After 30 minutes
stirring at 0.degree. C., a solution containing
(RS)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester (1 g,
5.34 mmol) and thioacetic acid (0.57 ml, 8 mmol) in THF (7 ml) was
added dropwise. The reaction mixture was stirred 30 minutes at
0.degree. C., 45 minutes at room temperature and concentrated. The
residue was chromatographed over silica gel (hexane-ethylacetate
9:1 then 8:2 then 1:1) to provide
(RS)-3-acetylsulfanyl-pyrrolidine-1-carboxylic acid tert-butyl
ester (1.4 g, 100%) as a slightly yellow oil, MS: m/e=246.3
(M+H.sup.+).
[0284] (RS)-3-Hydroxy-pyrrolidine-1-carboxylic acid tert-butyl
ester is a known compound and has been prepared as described in the
following reference: M. Bouygues; M. Medou; G. Quelever; J. C.
Chermann; M. Camplo; J. L. Kraus; Bioorg. Med. Chem. Lett.; 8; 3;
1998; 277-280
EXAMPLE 125
(RS)-2-Indan-2-yl-oxirane
[0285] To a mixture containing NaH (9.8 mg, 0.2 mmol) and
trimethylsulfoxoniumiodide (57.8 mg, 0.26 mmol) was added slowly
DMSO (0.44 ml). After 30 minutes stirring at room temperature, a
solution of indan-2-carbaldehyde (32 mg, 0.22 mmol) in DMSO (0.1
ml) was added. The reaction mixture was stirred 18 hours at room
temperature and then quenched with H.sub.2O. The aqueous phase was
extracted with ethylacetate, combined organic phases were dried
over Na.sub.2SO.sub.4, filtered and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 98:2) to
provide (RS)-2-indan-2-yl-oxirane (9 mg, 26%) as a colorless oil,
MS: m/e=160.0 (M.sup.+).
[0286] Indan-2-carbaldehyde is a known compound and has been
prepared as described in the following reference: Kenner; J. Chem.
Soc.; 105; 1914; 2694.
EXAMPLE 126
trans or cis-5-Phenyl-1-oxa-spiro[2.3]hexane
[0287] see Example 127.
EXAMPLE 127
cis or trans-5-Phenyl-1-oxa-spiro[2.3]hexane
[0288] To a solution of (3-methylene-cyclobutyl)-benzene (0.236 g.
1.64 mmol) in CH.sub.2Cl.sub.2 (3 ml) was added successively
methyltrioxorhenium (4 mg, 0.016 mmol), pyridine (15 .quadrature.l,
0.2 mmol) and H.sub.2O.sub.2 (0.22 ml, 35% in H.sub.2O). The
reaction mixture was stirred 7 hours at room temperature, diluted
with CH.sub.2Cl.sub.2, washed with H.sub.2O, dried over
Na.sub.2SO.sub.4 and concentrated. The residue was chromatographed
over silica gel (hexane-ethylacetate 98:2) to provide the compound
of example 126 trans or cis-5-phenyl-1-oxa-spiro[2,3- ]hexane (90
mg, first fraction, 35%) as a colorless oil, MS: m/e=159.2
(M-H.sup.+) and the compound of example 127 cis or
trans-5-phenyl-1-oxa-spiro[2,3]hexane (56 mg, second fraction, 21%)
as a colorless oil, MS: m/e=159.1 (M-H.sup.+).
EXAMPLE 128
(3-Methylene-cyclobutyl)-benzene
[0289] To a 2-3.degree. C. suspension of methyltriphenylphosphonium
bromide (0.36 g, 1 mmol) in THF (2.5 ml) was added dropwise n-BuLi
(0.69 ml, 1.1 mmol, 1.6 M in hexan). After 1 hour stirring at
0.degree. C., a solution of 3-phenyl-cyclobutanone (0.146 g, 1
mmol) in THF (1.5 ml) was added dropwise. The reaction mixture was
stirred 24 hours at room temperature and then diluted with hexane.
The so obtained precipitate was filtered and the filtrate was
concentrated. The residue was chromatographed over silica gel
(hexane-ethylacetate 9:1) to provide
(3-methylene-cyclobutyl)-benzene (57 mg, 40%) as a slightly yellow
oil, MS: m/e=144.1 (M.sup.+).
[0290] 3-Phenyl-cyclobutanone is a known compound and has been
prepared as described in the following reference: A. A. Frimer; J.
Weiss; H. E. Gottlieb; J. L. Wolk; J. Org. Chem.; 59; 4; 1994;
780-792.
EXAMPLE 129
3-Benzyl-cyclobutanone
[0291] A solution of (RS)-3-benzyl-2,2-dichlorocyclobutanone (0.3
g. 1.3 mmol) in acetic acid (3 ml) was refluxed for 1 hour in the
presence of zinc (0.86 g, 13.1 mmol. powder). The reaction mixture
was cooled to room temperature and filtered over decalite. The
filtrate was neutralized with saturated NaHCO.sub.3. The organic
phase was washed successively with H.sub.2O and brine, dried over
Na.sub.2SO.sub.4, and concentrated. The residue was chromatographed
over silica gel (hexane-ethylacetate 4:1) to provide
3-benzyl-cyclobutanone (0.16 g, 76%) as a colorless oil, MS:
m/e=160.2 (M.sup.+).
EXAMPLE 130
(RS)-3-Benzyl-2,2-dichlorocyclobutanone
[0292] To a room temperature mixture containing allylbenzene (1.84
g, 15.6 mmol), zinc-copper couple (5.1 g, 78 mmol) and diethylether
(60 ml) was added dropwise a solution of trichloroacetylchloride
(2.96 ml, 26.5 mmol) and phosphorus oxychloride (2.46 ml, 26.5
mmol) in diethylether (20 ml). The reaction mixture was stirred at
room temperature for 1 hour, filtered and the filtrate was
partially concentrated. The residue was neutralized with saturated
NaHCO.sub.3. The aqueous phase was extracted with diethylether. The
combined organic phases were washed successively with H.sub.2O and
brine, dried over Na.sub.2SO.sub.4, and concentrated. The residue
was chromatographed over silica gel (hexane) to provide
(RS)-3-benzyl-2,2-dichlorocyclobutanone (0.71 g, 20%) as a yellow
oil, MS: m/e=228.1 (M-H.sup.+).
EXAMPLE 131
Toluene-4-sulfonic acid 4-phenyl-but-3-ynyl ester
[0293] A mixture containing 3-butyn-1-ol 4-methylbenzenesulfonate
(0.45 g, 2 mmol), iodobenzene (0.45 g, 2.2 mmol), CuI (0.038 g, 0.2
mmol), triethylamine (1.01 g, 10 mmol) and
tetrakis(triphenylphosphine)palladium (0.12 g, 0.1 mmol) in toluene
(10 ml) was stirred 30 minutes at room temperature, and 2 hours at
65.degree. C. The reaction mixture was cooled to room temperature,
diluted with ethylacetate (10 ml), washed with H.sub.2O (10 ml),
dried over Na.sub.2SO.sub.4, and concentrated. The residue was
chromatographed over silica gel (hexane-ethylacetate 9:1 then 4:1)
to provide toluene-4-sulfonic acid 4-phenyl-but-3-ynyl ester (0.35
g. 58%) as a brown oil, MS: m/e=300 (M.sup.+).
[0294] 3-Butyn-1-ol 4-methylbenzenesulfonate is a known compound
and has been prepared as described in the following reference: E.
Bonfand; W. B. Motherwell; A. M. K. Pennell; M. K. Uddin; F.
Ujjainwalla; Heterocycles; 46; 1997; 523-534.
EXAMPLE 132
(2RS,3R)-2-Fluoro-1-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-4-pheny-
l-butan-1-one
[0295] (RS)-2-Fluoro-4-phenyl-butyric acid (0.66 g, 3.63 mmol) was
dissolved in DMF (5 ml) and carbonyldiimidazole (0.64 g, 3.8 mmol)
was added portionwise. After evolution of CO.sub.2 has ceased, the
reaction mixture was warmed to 55.degree. C. for 20 minutes and
then cooled to room temperature. A mixture of triethylamine (0.46
ml, 3.3 mmol) and (3R)-4-(pyrrolidin-3-ylsulfanyl)-phenol
trifluoroacetic acid (1.02 g, 3.3 mmol) in DMF (5 ml) was added.
The mixture was stirred at room temperature for 2 hours. The
solvent was removed in vacuo and the residue taken up in H.sub.2O
(30 ml).The mixture was extracted with ethylacetate (3.times.20
ml).The combined organic phases were dried over Na.sub.2SO.sub.4,
filtered and the solvent was removed in vacuo. The residue was
chromatographed over silica gel (CH.sub.2Cl.sub.2-MeOH, 99:1) to
provide
(2RS,3R)-2-fluoro-1-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin-1-
-yl]-4-phenyl-butan-1-one (1.12 g, 95%) as light yellow oil, MS:
m/e=359.1(M.sup.+).
[0296] The preparation of (3R)-4-(pyrrolidin-3-yl-sulfanyl)-phenol
trifluoroacetic acid is described in example 90.
[0297] Following the general method of example 132 the compound of
example 133 was prepared.
EXAMPLE 133
(2RS,3
S)-2-Fluoro-1-[3-(4-hydroxy-phenylsulfanyl)-pyrrolidin-1-yl]-4-phen-
yl-butan-1-one
[0298] The title compound, MS: m/e=360.2 (M+H.sup.+) was prepared
from (RS)-2-fluoro-4-phenyl-butyric acid and
(3S)-4-(pyrrolidin-3-yl-sulfanyl)- -phenol hydrobromide.
EXAMPLE 134
(3S)-4-[1-(2,2-Difluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0299] To a -60.degree. C. solution of oxalylchloride (0.21 ml,
2.42 mmol) in dry CH.sub.2Cl.sub.2 (4 ml) was added a solution of
DMSO (0.34 ml, 4.84 mmol) in CH.sub.2Cl.sub.2 (2 ml). After 5
minutes stirring, a solution of 2,2-difluoro-4-phenyl-butan-1-ol
(0.41 g, 2.2 mmol) in CH.sub.2Cl.sub.2 was added dropwise at
-60.degree. C. After 15 minutes stirring, triethylamine (1.54 ml,
11 mmol) was added dropwise, the reaction mixture was allowed to
warm up to room temperature and H.sub.2O (10 ml) was added. The
aqueous phase was extracted with CH.sub.2Cl.sub.2 (3.times.20
ml).The combined organic phases were dried over Na.sub.2SO.sub.4,
filtered and the solvent was removed in vacuo. The residue was
dissolved in 1,2-dichloroethane (15 ml) and added to a suspension
of (3S)-4-(pyrrolidin-3-ylsulfanyl)-phenol hydrobromide (0.68 g,
2.2 mmol), triethylamine (0.31 ml, 2.2 mmol) and sodium
triacetoxyborohydride (0.74 g, 3.30 mmol) in 1,2-dichloroethane (45
ml). Mixture was stirred at 65.degree. C. for 2 hours and overnight
at room temperature. H.sub.2O (30 ml) was added. The aqueous phase
was extracted with CH.sub.2Cl.sub.2 (3.times.20 ml).The combined
organic phases were dried over Na.sub.2SO.sub.4, filtered and the
solvent was removed in vacuo. The residue was chromatographed over
silica gel (hexane-ethylacetate 99:1 to 90:10) to provide
(3S)-4-[1-(2,2-difluoro-4--
phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol (0.55 g, 70%) as
light yellow oil, MS: m/e=364.2(M+H.sup.+).
[0300] Following the general method of example 134, the compound of
example 135 was prepared.
EXAMPLE 135
(3R)-4-[1-(2,2-Difluoro-4-phenyl-butyl)-pyrrolidin-3-ylsulfanyl]-phenol
[0301] The title compound, MS: m/e=364.2 (M+H.sup.+) was prepared
from 2,2-difluoro-4-phenyl-butan-1-ol and
(3R)-4-(pyrrolidin-3-ylsulfanyl)-phe- nol trifluoroacetic acid.
EXAMPLE 136
(RS)-2-Fluoro-4-phenyl-butyric acid
[0302] (RS)-2-Fluoro-4-phenyl-butyric acid methyl ester (0.39 g, 2
mmol) was added to a solution of KOH (0.56 g, 10 mmol) in EtOH (5
ml). After 1 hour stirring at room temperature, the reaction
mixture was concentrated, diluted with H.sub.2O (5 ml), acidified
to pH 1 with 2N HCl and extracted with CH.sub.2Cl.sub.2 (3 times).
The combined organic phases were dried over Na.sub.2SO.sub.4,
filtered and concentrated to provide (RS)-2-fluoro-4-phenyl-butyric
acid (0.343 g, 92%) as a colorless oil MS: m/e=182.1 (M.sup.+).
[0303] The preparation of (RS)-2-fluoro-4-phenyl-butyric acid
methyl ester is described example 122.
EXAMPLE 137
2,2-Difluoro-4-phenyl-butan-1-ol
[0304] 2,2-Difluoro-4-phenyl-butyric acid ethyl ester (0.23 g, 1
mmol) was dissolved in EtOH (4 ml) and treated with NaBH.sub.4
(39.4 mg, 1 mmol). After 30 minutes stirring at room temperature,
the reaction mixture was cooled to 0.degree. C., acidified to pH 1
with 1N HCl (2 ml), diluted with H.sub.2O (10 ml). The aqueous
phase was extracted with ether (3 times). The combined organic
phases were dried over Na.sub.2SO.sub.4, filtered and the solvent
was removed in vacuo. The residue was chromatographed over silica
gel (hexane-ethylacetate 99:1) to provide
2,2-difluoro-4-phenyl-butan-1-ol (0.11 g, 58%) as light yellow oil,
MS: m/e =186.1 (M.sup.+).
EXAMPLE 138
2,2-Difluoro-4-phenyl-butyric acid ethyl ester
[0305] Ethyl 2-oxo-4-phenylbutyrate (1 g, 4.7 mmol) was treated
with (diethylamino)sulfur trifluoride (1.3 ml, 9.4 mmol). After 2
hours stirring at room temperature, the reaction mixture was poured
on H.sub.2O-ice. The aqueous phase was extracted with
CH.sub.2Cl.sub.2 (2 times). The combined organic phases were washed
with H.sub.2O, dried over Na.sub.2SO.sub.4, filtered and the
solvent was removed in vacuo. The residue was distilled to provide
2,2-difluoro-4-phenyl-butyric acid ethyl ester (1.0 g, 94%) as
yellow oil, MS: m/e=228.1 (M.sup.+), b.p.: 90.degree. C., 0.2 mbar.
Ethyl 2-oxo-4-phenylbutyrate is a commercially available
compound.
EXAMPLE A
Tablet Formulation (Wet Granulation)
[0306]
2 Item Ingredients mg/tablet 1. Compound of formula 1 5 25 100 500
2. Lactose Anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4.
Microcrystalline Cellulose 30 30 30 150 5. Magnesium Stearate 1 1 1
1 Total 167 167 167 831
Manufacturing Procedure
[0307] 1 Mix items 1, 2, 3 and 4 and granulate with purified
water.
[0308] 2. Dry the granulation at 50.degree. C.
[0309] 3. Pass the granulation through suitable milling
equipment.
[0310] 4. Add item 5 and mix for three minutes; compress on a
suitable press.
EXAMPLE B
Capsule Formulation
[0311]
3 Item Ingredients mg/tablet 1. Compound of formula 1 5 25 100 500
2. Hydrous Lactose 159 123 148 -- 3. Corn Starch 25 35 40 70 4.
Talc 10 15 10 25 5. Magnesium Stearate 1 2 2 5 Total 200 200 300
600
Manufacturing Procedure
[0312] 1. Mix items 1, 2, and 3 in a suitable mixer for 30
minutes.
[0313] 2. Add items 4 and 5 and mix for 3 minutes.
[0314] 3. Fill into a suitable capsule.
[0315] 4. Add item 5 and mix for three minutes; compress on a
suitable press.
* * * * *